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1RÉSUMÉ 
 Le diabète de type 1 ou 2 pré-grossesse altère-t-il l’acide docosahexaénoïque et l’acide 
arachidonique dans le sang de cordon et le neuro-développement du nouveau-né? 
 
Par 
Hilary Chappus-McCendie 
Programmes de Physiologie 
 
Mémoire présenté à la Faculté de médecine et des sciences de la santé en vue de l’obtention 
du diplôme de maitre ès sciences (M.Sc.) en Physiologie, Faculté de médecine et des 
sciences de la santé, Université de Sherbrooke, Sherbrooke, Québec, Canada, J1H 5N4 
 
La prévalence des grossesses avec diabète augmente sans cesse et cela peut engendrer 
des conséquences  pour l’enfant, tel  que des scores cognitifs  plus faibles. L'acide 
docosahexaénoïque (DHA) et l'acide arachidonique (AA) sont importants pour le 
développement cérébral du fœtus. Ces acides gras doivent provenir de l’alimentation puisque 
l’humain ne peut les fabriquer et leur transfert de la mère au fœtus dans les grossesses avec 
diabète semble être  modifié. D’aileurs, dans les  grossesses compliquées  par le  diabète 
gestationnel (GDM), le pourcentage relatif de DHA est plus élevé dans le plasma des mères 
mais plus faible dans le sang de cordon par rapport aux contrôles sans diabète. Nous pensons 
que dans chez les mères avec un diabète diagnostiqué avant la grossesse, le transfert de DHA 
vers le fœtus sera moins efficace puisque ces femmes ont des hypo- et hyperglycémies plus 
fréquentes. Par conséquent, notre hypothèse est que, pendant la grossesse, les femmes avec 
un diabète de type 1 et de type 2 (DT1; DT2) diagnostiqué avant la grosses auront un transfert 
plus faible de  DHA et  d'AA  de la  mère au fœtus, ce  qui aura  pour conséquence  un 
neurodéveloppement plus faible de leur nouveau-né. Sept femmes enceintes avec un DT1 ou 
un DT2 préexistant et 26 sans diabète ont été recrutées. Le profil en acides gras des lipides 
totaux du plasma maternel, du sérum et du sang du cordon ombilical, et du placenta maternel 
et fœtal a été efectué. Une électroencéphalographie a été effectué chez le nouveau-né 24-48 
heures après la  naissance et  48 semaines post-aménorrhée. Nos résultats  montrent  que la 
concentration d'AA, mais non de DHA, était significativement plus faible dans les lipides 
totaux  du sérum  du cordon  des  participantes  diabétiques comparativement aux non-
diabétiques mais que le niveaux d’AA dans le plasma maternel n’était pas différent entre les 
groupes. Ce résultat suggère un potentiel dysfonctionnement du transfert de l’AA dans le 
placenta mais  nos résultats  n’ont  pas  montré d'accumulation  d'AA  ou  de  DHA  dans le 
placenta maternel ou fœtal. Malgré ce transfert plus faible de l'AA, le neurodéveloppement 
des  nouveau-nés tel  qu’évalué  par électroencéphalographie était similaire  dans les  deux 
groupes. Bien que les résultats démontrent un transfert plus faible d'AA de la mère au fœtus 
dans les grossesses avec diabète, ils n'expliquent pas le mécanisme. L'étude des niveaux de 
transporteurs d'acides gras placentaires et des niveaux d'AA dans différents classes lipidiques 
permetrait de mieux comprendre ce mécanisme. 
Mots clés: Diabète de type 1, diabète de type 2, grossesse, acide docosahexaénoïque, acide 
arachidonique, neuro-développement, électroencéphalographie 
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2SUMMARY 
 Does pre-existing type 1 and type 2 diabetes during pregnancy lower 
docosahexaenoic acid and arachidonic acid in the umbilical cord blood of newborns 
and thus interfere with neurodevelopment? 
 
By 
Hilary Chappus-McCendie 
Physiology Program 
 
Thesis presented at the Faculty of medicine and health sciences for the obtention of Master 
degree diploma maitre ès sciences (M.Sc.) in Physiology, Faculty of medicine and health 
sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada, J1H 5N4 
 
The  prevalence  of  diabetic  pregnancies has  been increasing over the last several 
decades.  Diabetic pregnancies are associated  with long-term  negative  outcomes for the 
offspring, including lower cognitive scores. Several  groups  have also investigated the 
transfer of docosahexaenoic acid (DHA) and arachidonic acid (AA) from mother to fetus in 
diabetic pregnancies, since these faty acids are important for fetal brain development. These 
faty acids  must  be  obtained through the  diet since  humans cannot  make them. Previous 
studies have shown that in pregnancies complicated by gestational diabetes melitus (GDM), 
relative percentage of DHA is higher in the plasma of GDM mothers but lower in the cord 
blood of GDM mothers compared to controls. We believe that in pre-existing diabetes, the 
transfer  of  DHA and  AA to the fetus  wil  be less eficient  given the greater frequency  of 
hypo- and hyperglycemia in these women. Therefore, we hypothesize that pre-existing type 
1 and type 2 diabetes (T1D and T2D) during pregnancy lowers the transfer of DHA and AA 
from mother to fetus which results in lower neurodevelopment of the neonate. 
Seven pregnant women with pre-existing T1D or T2D and 26 without diabetes were 
recruited. The faty acid profile of the total lipids from the maternal plasma, umbilical cord 
serum and  whole  blood, and the  maternal and fetal  placenta were  performed. An 
electroencephalography in the neonate was also performed 24-48 hours after birth and 48 
weeks post-amenorrhea. 
AA concentration, but not DHA, was significantly lower in the umbilical cord serum 
total lipids of the diabetic group compared to the non-diabetic group. However, AA levels in 
the maternal plasma were similar between diabetic and non-diabetic groups. This indicates 
that there may be a dysfunction at the level of the placenta which results in a lower transfer 
of AA to the fetus in diabetic pregnancies. However, there was no accumulation of AA or 
DHA in the maternal or fetal sides placenta. Despite the lower transfer of AA from mother 
to fetus in the diabetic group, there was no evidence of impaired neurodevelopment in the 
EEGs  of the  neonates from the  diabetic  group at either time  point.  While the results 
demonstrate lower transfer of AA from mother to fetus in diabetic pregnancies, they do not 
explain the mechanism. The investigation of placental faty acid transporter levels and AA 
levels in different lipid pools would aid to further clarify this mechanism. 
 
Keywords: Type 1 diabetes, type 2 diabetes, pregnancy, docosahexaenoic acid, arachidonic 
acid, neurodevelopment, electroencephalography 
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1INTRODUCTION 
 
Diabetes Melitus 
Definition and prevalence 
Diabetes melitus is a chronic metabolic disorder that causes hyperglycemia due to 
impaired insulin secretion, defective insulin action, or both (Punthakee et al., 2018). Chronic 
hyperglycemia is associated  with a  number  of complications including cardiovascular 
disease,  neuropathy,  diabetic  nephropathy, and  diabetic retinopathy.  According to results 
from the 9th edition of the International Diabetes Federation (IDF) Diabetes Atlas, the global 
prevalence of diabetes in 2019 was estimated to be 463 milion people, or 9.3% of the world’s 
adult population (Saeedi et al., 2019). Moreover, the IDF Diabetes Atlas results projected 
that diabetes prevalence is increasing: Worldwide diabetes prevalence wil increase to 578 
milion (10.2%  global  population) in  2030 and  700  milion (10.9%  global  population) in 
2045 (Saeedi et al., 2019). Similar trends are being echoed in Canada. According to Diabetes 
Canada, the estimated prevalence of diagnosed type 1 and type 2 diabetes cases was 3.655 
milion (9% of Canadians) in 2019 and this number is expected to increase to 4.785 milion 
(11%)  by  2029 (Diabetes  Canada,  2019).  Moreover, it is likely that  many  Canadians are 
living with undiagnosed type 2 diabetes and prediabetes, a condition in which individuals 
have elevated blood glucose levels which put them at a higher risk of developing diabetes 
(Punthakee et al., 2018). The prevalence of Canadians with type 1 diabetes, diagnosed and 
undiagnosed type 2 diabetes, and prediabetes was estimated to be almost 11 milion (29%) 
in 2019 and is expected to increase to over 13.3 milion (32%) by 2029 (Diabetes Canada, 
2019). 
There are three main categories of diabetes melitus: Type 1, type 2, and gestational 
diabetes melitus. Type 1 diabetes melitus (T1D) accounts for approximately 5-10% of those 
diagnosed  with  diabetes (American  Diabetes  Association,  2008).  T1D is caused  by the 
destruction of the beta cels of the pancreas (Punthakee et al., 2018). Pancreatic beta cels 
produce insulin, and therefore their  destruction leads to insulin  deficiency.  Beta cel 
destruction may be immune-mediated or idiopathic (American Diabetes Association, 2015 
#2). Individuals with T1D are typicaly diagnosed earlier in life (age of diagnosis < 25 years), 
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do  not  usualy  have a family  history  of  diabetes, and are  prone to  diabetic  ketoacidosis 
(Punthakee et  al.,  2018).  Type  2  diabetes  melitus (T2D) accounts for  90-95%  of total 
diabetes cases (American  Diabetes  Association,  2008).  T2D is characterized  by insulin 
resistance with relative insulin deficiency (American Diabetes Association, 2015). Unlike 
T1D, T2D is not associated with auto-immune destruction of pancreatic beta cels or diabetic 
ketoacidosis (American  Diabetes  Association,  2015). Individuals  with  T2D are typicaly 
diagnosed later in life (age  of  diagnosis  >  25  years), frequently  have a family  history  of 
diabetes, and tend to present obesity (Punthakee et al., 2018). Lastly, gestational diabetes 
melitus (GDM) is defined as glucose intolerance with first onset during pregnancy (Baz et 
al., 2016). GDM is typicaly diagnosed using a 50 g glucose chalenge test and/or a 75 g oral 
glucose tolerance test at 24-28 weeks of gestation (Feig et al., 2018). 
As previously mentioned, the number of diabetes cases is increasing (Saeedi et al., 
2019 and Diabetes Canada, 2019). The increase in T2D cases, which make up approximately 
90% of total diabetes cases, is associated with aging, urbanization, and the obesity epidemic 
(Saeedi et  al.,  2019).  Similarly,  T1D incidence is also increasing,  but the cause  of this is 
unclear (Paterson et al., 2009). In line with this trend, the prevalence of diabetes in women 
of childbearing age is also increasing.  According to a  population-based cohort study  of 
1,109,605 women in Ontario who gave birth between 1996 and 2010, the rate of GDM and 
pre-existing  diabetes (T1D and  T2D)  during  pregnancy  doubled  during this time  period 
(GDM  prevalence increased from  2.7% to  5.6% and  T1D and  T2D  prevalence increased 
from 0.7% to 1.5%) (Feig et al., 2014). In addition, the authors found that the rate of both 
GDM and pre-existing T1D and T2D during pregnancy was consistently higher in women 
aged ≥ 30 years compared to women aged 15-29 years (Feig et al., 2014). By the year 2010, 
almost 1 in every 10 pregnant woman ≥ 30 years of age had GDM (7.4%) or pre-existing 
T1D or T2D (1.9%) (Feig et al., 2014).  
 
Diabetes during pregnancy and its associated outcomes 
 Diabetic pregnancies can be divided into two main categories: GDM and pre-existing 
diabetes. In the case of GDM pregnancies, the glucose intolerance first develops or is first 
recognized during the pregnancy (Baz et al., 2016). On the other hand, pre-existing diabetes 
during pregnancy consists of the pregnant woman having T1D or T2D diagnosed prior to the 
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pregnancy.  This  means that in the case  of  pre-existing  diabetes, the  dificulties in  blood 
glucose control are present from the beginning of the pregnancy. Therefore, in the case of 
pre-existing  T1D and  T2D  during  pregnancy, the fetus may  be exposed to the impaired 
glucose control from conception. This is in contrast to GDM pregnancies, where typicaly 
the  glucose intolerance  develops along the course  of the  pregnancy and thus the fetus is 
exposed to elevated blood glucose levels for a shorter period of time. Before discussing the 
potential impact of this difference in the exposure time to hyperglycemia in pregnancies with 
pre-existing diabetes versus GDM, we wil explore the role of maternal glucose levels during 
pregnancy and how they may impact the fetus.  
 
Glucose metabolism in normal pregnancies 
 Over the course of pregnancy, the mother’s metabolism must adjust in order to meet 
the increasing needs of the fetus to ensure growth, development, and adequate energy stores. 
These changes in metabolism are also required to meet the increasing physiological demands 
of pregnancy as wel as to ensure that the mother has enough energy stores for during and 
after the pregnancy (Hadden and McLaughlin, 2009). Glucose is an important substrate for 
the human fetus and must be consistently available in sufficient amounts to meet the needs 
of the growing fetus. There are two main aspects of carbohydrate metabolism that change 
during pregnancy: decreasing fasting glucose levels and a gradual increase in postprandial 
glucose and insulin secretion (Hadden and  McLaughlin,  2009).  During early  pregnancy, 
fasting glucose levels have been known to decrease, likely due to increased maternal plasma 
volume (Hadden and  McLaughlin,  2009).  Fasting  glucose levels are  measured  during the 
fasting state, during which insulin levels are low and the liver produces glucose in order to 
fuel the  brain, red  blood cels, and  other  organs in the absence  of food intake.  As the 
pregnancy  progresses, fetoplacental  glucose  utilization increases  which also  decreases 
fasting plasma glucose levels (Hadden and McLaughlin, 2009). As previously mentioned, 
pregnancy is also associated with a gradual increase in postprandial plasma glucose levels 
and increased insulin secretion. Normaly, insulin secretion would trigger uptake of glucose 
by muscles and adipose tissue and would inhibit the release of glucose by the liver, resulting 
in a subsequent decrease in glucose levels. However, in the case of pregnancy, there is also 
a decrease in insulin sensitivity (Bute, 2000 and Hadden and McLaughlin, 2009). A decrease 
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in insulin sensitivity means that more insulin is produced in response to food consumption 
and that nutrients such as glucose remain in the blood for longer. Moreover, decreased insulin 
sensitivity  of the liver results in increased  hepatic  output  of  glucose (Hadden and 
McLaughlin, 2009). Taken together, this al results in higher post-prandial glucose levels and 
therefore increased availability of glucose for the fetus. 
 
Blood glucose control in diabetic pregnancies 
 It is clear that a tight control of glucose metabolism over the course of pregnancy is 
necessary in  order to  provide enough  glucose for fetal  development.  This then  poses a 
problem for diabetic pregnancies wherein glucose metabolism is altered. In the case of T1D, 
pancreatic beta cels are no longer able to produce insulin. This results in insulin deficiency 
and therefore elevated blood glucose levels. Normal blood glucose levels must be maintained 
through the administration of exogenous insulin (American Diabetes Association, 2015). On 
the other hand, in pregnancies complicated by T2D, uncontroled blood glucose levels are 
caused by insulin resistance with relative insulin deficiency (American Diabetes Association, 
2015). In addition,  T2D is  often associated  with  obesity,  hypertension, and  other 
comorbidities which also increase the risk of pregnancy complications (American Diabetes 
Association,  2015).  Proper  management  of  blood  glucose levels can  be  difficult in 
pregnancies complicated  by either  T1D  or  T2D and therefore these individuals are at a 
greater risk for hyper- and hypo-glycemic episodes (American Diabetes Association, 2015 
and  Murphy et  al.,  2007).  One study  performed continuous  glucose  monitoring in  40 
pregnant women with T1D and 17 pregnant women with T2D throughout their pregnancies 
to gain insight into how glucose levels change over the course of the day in these populations 
(Murphy et al., 2007). The authors observed no difference in A1c between T1D and T2D 
participants over the course of gestation (Murphy et al., 2007). The authors also found that 
at  8  weeks  of  gestation, individuals from  both the  T1D and  T2D  group experienced 
hyperglycemia (blood  glucose levels  >  140  mg/dL) for  more than  40%  of their  day 
(approximately 10 hours per day) (Murphy et al., 2007). Percentage of time spent per day in 
hyperglycemia decreased for both groups over the course of gestation; percentage of time 
spent hyperglycemic decreased from 41% at the end of the first trimester to 33% at the end 
of the third trimester for T1D participants and 33% at the end of the first trimester to 12% at 
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the end of the third trimester for T2D participants (Murphy et al., 2007). They also found 
that proportion of time spent hypoglycemic did not change significantly for either groups 
throughout pregnancy (Murphy et al., 2007). Moreover, women with T1D tended to spend 
more time hypoglycemic (blood glucose level <70 mg/dL and <50 mg/dL) than women with 
T2D (3.3 hours per day vs. 2.3 hours per day) (Murphy et al., 2007). Despite spending less 
time in hypoglycemia during the day, T2D women were found to have an equivalent risk for 
nocturnal hypoglycemia to that of the T1D participants (Murphy et al., 2007). This study 
confirms that both T1D and T2D during pregnancy can lead to both hypo- and hyperglycemic 
episodes during al three trimesters of pregnancy. This means that the fetus is exposed to a 
hypoglycemic and  hyperglycemic environment from the  beginning  of  gestation.  This 
contrasts with GDM, where glucose intolerance develops over the course of the pregnancy 
and therefore the fetus  may  not  be exposed to these  hypo- and  hyperglycemic from the 
beginning of gestation. 
 Lack  of  blood  glucose control  during  pregnancy can  potentialy lead to 
complications. For instance, a meta-analysis of 25 reports that included data on 207,172 non-
diabetic  pregnant  women  who received  oral  glucose tolerance tests found that there  were 
positive linear associations between maternal glucose concentrations and cesarean section, 
induction  of labor, large for  gestational age (LGA),  macrosomia, and shoulder  dystocia 
(Farrar et al., 2016). Furthermore, a retrospective case-control study of pregnancies in which 
the women underwent a second trimester 1-hour oral glucose chalenge test found that the 
hypoglycemic group had an increased rate of admission to special/neonatal intensive care 
units (Feinberg et  al.,  2005).  Moreover, frequent  maternal  hypoglycemia can also  be 
associated  with intrauterine  growth restriction (American  Diabetes  Association,  2015). 
Given the increased occurrence of hypoglycemia and hyperglycemia in diabetic pregnancies, 
it would be logical to think that diabetic pregnancies would result in similar complications 
found in the Farrar and Feinberg studies. The folowing sections wil discuss the short- and 
long-term outcomes of diabetic pregnancies. 
 
Short-term negative outcomes of diabetic pregnancies 
Unsurprisingly, the same complications found in the  Farrar and  Feinberg studies 
discussed in the previous section are also associated with diabetic pregnancies. A population-
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based cohort study of 1,109,605 women who gave birth in Ontario between 1996-2010 found 
that in women with pre-existing T1D and T2D, there was an 86% increased risk of having 
an infant with congenital anomalies and a 133% increased risk of perinatal death compared 
to women without diabetes (Feig et al., 2014). That same study reported that women with 
GDM had a 26% higher risk of having an infant with congenital anomalies and a lower risk 
of  perinatal  death (relative risk  0.63) compared to  women  without  diabetes (Feig et  al., 
2014). A greater risk for congenital anomalies and perinatal death in diabetic pregnancies 
compared to non-diabetic pregnancies were also found in other cohorts (Lai et al., 2016 and 
Tennant et al., 2014). 
Several studies reported a greater risk for cesarean section in women with diabetic 
pregnancies compared to non-diabetic women (Buhary et al., 2016, Kothari & Lim, 2014, 
Catalano et al., 2012, Cundy et al. 2013, and Lai et al., 2016). The risk for cesarean section 
is greatest in pregnant women with T1D and T2D compared to those with GDM (Kathori & 
Lim, 2014 and Lai et al., 2016). Moreover, the risk of cesarean section is even greater in 
pregnant women with T1D, T2D, and GDM who have elevated glycated hemoglobin (A1C) 
levels (>6.5%) compared to those with normal A1C levels (Buhary et al. 2016). Pregnant 
women with pre-existing diabetes and GDM also have a greater risk for other pregnancy and 
delivery complications such as  miscarriage (Buhary et  al. 2016 and  Alessi et  al., 2018), 
polyhydramnios (Kothari & Lim, 2014), preterm delivery (Lai et al. 2016 and Alessi et al., 
2018),  neonatal intensive care  unit (NICU) admission (Lai et  al.  2016 and  Alessi et  al., 
2018), shoulder dystocia (Catalano et al., 2012, Kotari & Lim, 2014 and Lai et al., 2016), 
and hypertension and pre-eclampsia (Catalano et al., 2012, Lai et al. 2016 and Alessi et al., 
2018). 
Diabetic pregnancies often result in infants with higher birth weight and increased 
adiposity. The risk of fetal macrosomia, a condition in which the neonate weighs more than 
4000 grams, is greatest in pregnancies complicated by pre-existing T1D and T2D, folowed 
by those complicated by GDM, compared to non-diabetic pregnancies (Lai et al., 2016). One 
study found that the risk for fetal macrosomia was higher in pregnant women with T1D, T2D 
and GDM who have elevated A1C levels compared to those with normal A1C levels (Buhary 
et al., 2016). Another study found that pregnancies complicated by both GDM and obesity 
had an increased odds ratio of neonates with birth weight and body fat percentage greater 
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than the 90th percentile compared to those complicated by GDM or obesity alone (Catalano 
et al., 2012). These complications are thought to be the result of fetal hyperinsulinemia as a 
response to elevated levels of maternal blood glucose levels in diabetic pregnancies (Burlina 
et al., 2017). 
 
Long-term negative outcomes for ofspring of diabetic pregnancies 
 There are several long-term consequences of diabetic pregnancies that can negatively 
impact the offspring throughout their lives. Diabetic pregnancies are thought to be associated 
with two  main categories  of long-term complications.  The first is related to  obesity and 
metabolic problems and the second category is related to cognitive function. The folowing 
sections wil discuss these long-term complications in more detail. 
 
Metabolic syndrome, increased body mass index, and Type 2 Diabetes 
Offspring  of  diabetic  pregnancies are at a  greater risk  of  developing  metabolic 
syndrome, a  group  of conditions (abdominal  obesity,  high  blood triglyceride (TG) levels, 
low levels  of high-density lipoprotein (HDL) cholesterol,  high  blood  pressure, and  high 
fasting blood glucose) which increase an individual’s risk for heart disease, stroke, and T2D 
(Clausen et al., 2009). A folow-up study examined the risk of overweight and metabolic 
syndrome in adult ofspring of mothers with diet-treated GDM, T1D, and with risk indicators 
for GDM. The participants with GDM had a higher fasting (5.2 vs. 4.7 mmol/liter) and 2-
hour blood glucose (7.8 vs. 5.2 mmol/liter) compared to the participants with risk indicators 
for GDM. The mean blood glucose of T1D participants was 8.9 mmol/liter and 6.8 mmol/liter 
in the first and third trimesters, respectively.  With regard to the  offspring, the authors 
observed that al three  groups  of  ofspring  had a significantly  higher risk for  metabolic 
syndrome than offspring from the background population (Clausen et al., 2009). Similarly, 
another study found that offspring of mothers with T1D had a higher prevalence of metabolic 
syndrome compared to offspring of non-diabetic mothers (Vlachová et al., 2015). 
Several studies have also found a link between diabetes during pregnancy and higher 
offspring body mass index (BMI) and obesity risk. One study found that by eight years of 
age, approximately half of the offspring from the diabetic mothers group weighed greater 
than the  90th percentile for  weight (Silverman et  al.,  1991). This  higher  weight in the 
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offspring  of  diabetic  mothers  was  positively corelated  with the  mothers’  weight  before 
pregnancy and  with amniotic fluid insulin at  32-38  weeks  of  gestation (Silverman et  al., 
1991). In that same cohort, the mean BMI of ofspring of diabetic mothers was 24.6 ± 5.8 
kg/m2 compared to 20.9 ± 3.4 kg/m2 in the ofspring of control mothers by 14-17 years of 
age (Silverman et al., 1998). The authors observed an association between childhood obesity 
adolescence and  offspring sex,  maternal  weight, and amniotic fluid insulin concentration 
(Silverman et al., 1998). Another study found that the BMI standard deviation score between 
1-14 years of age was highest in LGA and non-LGA offspring of T2D mothers, compared to 
LGA and non-LGA offspring of T1D and GDM mothers (Hammoud et al., 2018). They also 
examined several covariates (maternal age at pregnancy, parity, maternal education level and 
employment,  maternal and  paternal ethnicity,  maternal  pre-pregnancy  BMI, and current 
paternal BMI) and found that none of them had a statisticaly significant impact on the slope 
of the BMI models (Hammoud et al., 2018). In addition, another study found that offspring 
of mothers with diet-treated GDM and T1D had double the risk of being overweight (BMI ≥ 
25  kg/m2) at  18-27  years  of age compared to  ofspring from the  background  population 
(Clausen et al., 2009). Moreover, this risk remained statisticaly significant after adjustment 
for  maternal age at  delivery,  maternal  pre-pregnancy  BMI,  ofspring age, family 
occupational social class, and  maternal  hypertension at first  visit (Clausen et  al.,  2009). 
Similarly, another study found that adolescent offspring of mothers with T1D had a higher 
BMI standard  deviation score compared to  ofspring  of  non-diabetic  mothers after 
adjustment for  maternal  pre-pregnancy  BMI and  pubertal  development (Vlachová et  al., 
2015). Finaly, another study that compared BMI between siblings who were born before 
and after their mother was diagnosed with T2D revealed that the mean BMI was 2.6 kg/m2 
higher in siblings born after their mother developed T2D compared to those born prior to the 
diagnosis (while controling for sibship) (Dabelea et al., 2000). 
Offspring of diabetic pregnancies are also at a greater risk of developing prediabetes 
and T2D. In a folow-up study of 18-27 years old offspring of mothers with GDM or T1D, 
the adjusted odds ratio for offspring pre-diabetes/T2D (adjusted for maternal family history 
of diabetes, the mother’s weight, and the age of the offspring) was 7.76 in offspring of GDM 
mothers and  4.02 in  offspring  of  T1D  mothers compared to  offspring  of the  background 
population (Clausen et  al.,  2008). In the  previously  mentioned study  which compared 
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siblings who were born before and after their mother was diagnosed with T2D, the authors 
reported that the siblings  who  were  born after the  mother  developed  T2D  were at a 
significantly higher risk of developing T2D than their siblings who were born before their 
mother’s diagnosis (Dabelea et al., 2000). 
 
Cognitive abilities 
While the link  between  maternal  diabetes  during  pregnancy and  higher  ofspring 
BMI and risk for metabolic syndrome and T2D is relatively intuitive, the connection between 
maternal  diabetes and the  ofspring’s cognitive abilities  may  not  be as evident. In short, 
glucose is transported to the fetus  via the  placenta  based  on the  maternal-to-fetal glucose 
concentration gradient (Burlina et al., 2017). This means that if maternal blood glucose levels 
are elevated, then more glucose is transferred to the fetus. Maternal insulin, however, cannot 
cross the placenta (Burlina et al., 2017). Therefore, the fetus must produce its own insulin in 
response to the elevated level  of  glucose influx.  Maternal  hyperglycemia  often seen in 
diabetic pregnancies can lead to hyperplasia of the pancreatic beta cels in the fetus which 
accelerates the fetus’s ability to produce insulin in utero (Burlina et al., 2017). Once born, 
the neonate is no longer exposed to its mother’s hyperglycemia via the placenta and therefore 
experiences  hypoglycemia.  Neonatal  hypoglycemia is associated  with increased  maternal 
blood glucose levels during pregnancy (Burlina et al., 2017, Buhary et al., 2016, and Farrar 
et  al.,  2016). It seems that  both  maternal  hyperglycemia  during  pregnancy and  neonate 
hypoglycemia can be detrimental for the developing brain. For instance, one study in rats 
found that  maternal  hyperglycemia  was associated  with the retardation  of  dendritic 
development in the fetal brain (Jing et al., 2014). Another study in rats revealed that maternal 
diabetes-induced  hyperglycemia and intracerebral  hyperinsulinism  decrease fetal  brain 
concentrations  of  neuropeptide  Y, a  neurotransmiter that  mediates several  biological 
functions including cel neurogenesis (Singh et al., 1997). In addition, another group reported 
that severe  uncontroled  hyperglycemia in  pregnant rats resulted in  neurodevelopmental 
delay in the pups as wel as a deregulation of the expression of proteins involved in apoptosis, 
celular survival, and  neuroinflammation in the  hippocampus  of the  pups (Piazza et  al., 
2019). In terms  of  neonatal  hypoglycemia, a systematic review  of eighteen studies that 
assessed the effect of neonatal hypoglycemia on neurodevelopment in humans found that the 
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results  were  mixed,  with some finding  no diferences and  others reporting serious  brain 
damage folowing neonatal hypoglycemic episodes (Boluyt et al., 2006). 
Given the potential link between maternal hyperglycemia during pregnancy, neonatal 
hypoglycemia and  disturbances in  neurodevelopment, several studies  have compared 
cognitive measures in offspring of diabetic and non-diabetic mothers (Brincioti et al., 2009, 
de  Regnier et  al.,  2000,  Silverman et  al.,  1998,  Fraser et  al.,  2012,  Clausen et  al.,  2013, 
Temple et al., 2011, Bytoft et al., 2016, Clausen et al., 2011, Xiang et al., 2018, and Bytoft 
et  al.,  2017).  One study reported that average IQ scores at ages  3-5  years  were inversely 
correlated  with  maternal  blood β-hydroxybutyrate and free faty acid levels in the third 
trimester (Silverman et al., 1998). Similarly, the authors also reported that average IQ scores 
of offspring of diabetic mothers at ages 7-11 years were inversely corelated with maternal 
A1C levels in the 2nd trimester and β-hydroxybutyrate levels in the 3rd trimester (Silverman 
et  al.,  1998).  Another study found that  pre-existing  diabetes  during  pregnancy and  GDM 
were associated with lower average School Entry Assessment scores at age 4, lower age IQ 
scores at age 8, and lower educational atainment at age 16 in ofspring of diabetic mothers 
compared to offspring of non-diabetic mothers after adjustment for offspring sex, maternal 
age,  pre-pregnancy  BMI, smoking,  parity, cesarean section,  maternal education, and 
occupational social class (Fraser et  al.,  2012). It was also reported that adult  offspring  of 
mothers with GDM had lower global cognitive scores than ofspring from the background 
population,  however the  difference  was  not statisticaly significant after adjustment for 
several wel-known predictors of cognitive function (Clausen et al., 2013). Studies have also 
reported that ofspring of mothers with T1D had normal overal IQ scores but poorer working 
memory at ages 6-12 years (Temple et al., 2011), lower scores in composite inteligence, 
verbal inteligence,  nonverbal inteligence, and composite  memory  during adolescence 
(Bytoft et al., 2016), and lower global cognitive scores in adulthood (Clausen et al., 2011) 
compared to ofspring of non-diabetic mothers. 
It has also been hypothesized that diabetes during pregnancy may also be associated 
with atention deficits in the offspring. For instance, a recent retrospective birth cohort study 
of  333,182 individuals  born  between  1995-2012 found that the  hazard ratio for atention 
deficit  hyperactivity  disorder (ADHD) in  offspring at the  4-year folow-up  was  1.57 for 
offspring of T1D mothers, 1.43 for offspring of T2D mothers, 1.26 for offspring of mother 
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with GDM requiring anti-diabetes medication, and 0.93 for offspring of mothers with GDM 
that did not require medication (Xiang et al., 2018). In contrast, another study that assessed 
atention deficits in 269 adolescent offspring of mothers with T1D did not find any clinicaly 
significant differences atention deficit scores in adolescents from T1D mothers compared to 
those from non-diabetic mothers (Bytoft et al., 2017).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  1. Types  of  brain  waves in electroencephalography (EEG) recording.  EEG  brain 
waves are classified based on frequency and correspond to different types of brain activity. 
Image of EEG waves was modified from Abhang et al., 2016. 
 
Electroencephalography 
 Since most cognitive tests cannot be performed in humans less than one year of age, 
there is limited information about the neurodevelopment of neonates from diabetic mothers 
after birth. While magnetic resonance imaging (MRI) can be used to assess structural brain 
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development, it might be considered to be too invasive to perform in infants without there 
being any clinical rationale for the infant’s health. Electroencephalography (EEG) is a 
recording of the brain’s electrical activity using electrodes placed along the subject’s scalp. 
EEG is a non-invasive way to detect subtle differences in brain activity and can be 
performed soon after birth. EEG recordings result in oscilating paterns of brain activity or 
brain waves which difer in frequency based on the state of the brain or the task it is 
performing (Marzbani et al., 2016) (Figure 1). Frequency is a measure of the number of 
waves per second (Hertz (Hz). Brainwaves can be classified into the folowing five 
categories based on their frequency range: Delta (0 – 3.4 Hz), Theta (3.5 – 7.4 Hz), Alpha 
(7.5 – 12.9 Hz), Beta (13.0 – 20.0 Hz), and Gamma (30 – 100 Hz) (Marzbani et al., 2016 
and Léveilé et al., 2018). The exact values of the frequency ranges vary depending on the 
study. Each type of brain wave corresponds to diferent states or various tasks performed 
by the brain. In the mature brain, delta waves (0 – 3.4 Hz) are associated with sleep and 
dreaming, theta waves (3.5 – 7.4 Hz) are associated with drowsiness, alpha waves (7.5 – 
12.9 Hz) are associated with both a relaxed and awake state, beta waves (13.0 – 20.0 Hz) 
are associated with thinking and alertness, and finaly gamma waves (30 – 100 Hz) are 
associated with problem solving (Marzbani et al., 2016). 
In the case  of the  developing  brain,  brain activity changes in  order to  meet the 
increased  demand for computational load. In  particular,  brain activity increases in both 
variability and complexity with age (Vakorin et al., 2011, Costa et al., 2002, and Lippé et 
al., 2009). Vakorin and coleagues assessed the complexity of brain signals in response to 
auditory and visual stimuli using scalp-recorded EEG measurements in 35 children aged 27 
days to 5 years and 5 months (Vakorin et al., 2011). The authors found that developmental 
changes were explained by a decrease in the local processing of information, with a peak in 
the alpha frequency range, as wel as an increase in synchronization in the delta, theta and 
alpha rhythms (Vakorin et al., 2011). Moreover, the authors observed an association between 
brain  development and  desynchronization effects in the  higher  beta to lower  gamma 
frequency ranges (Vakorin et al., 2011). To this writer’s knowledge, four studies reported 
using EEG to evaluate neurodevelopment in the ofspring of diabetic mothers (Castro Conde 
et al., 2013, Brincioti et al., 2009, de Regnier et al., 2000, and Léveilé et al., 2018). One of 
said studies  performed 90-minte video-EEG recordings in  23 ful-term  neonates  of  T1D 
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mothers and 22 from non-diabetic mothers 48 – 72 hours after birth with the goal of recording 
at least one complete sleep-wake cycle (Castro Conde et al., 2013). The authors found that 
the  video-EEG recordings from  newborns from  T1D  mothers indicated abnormal 
development and  brain function.  Notably, the authors  observed that infants  of  diabetic 
mothers had a higher percentage of indeterminate sleep, higher percentage of discontinuity, 
higher  percentage  of δ  brushes in the  bursts,  higher  duration  of inter-burst intervals, less 
encoches frontales, less θ/α Rolandic activity, and more transient sharp waves (Castro Conde 
et al., 2013). In addition, the infants of diabetic mothers with a maternal A1c ≥ 6% in the 
first and second trimester of pregnancy exhibited a greater percentage of δ brushes in the 
burst compared to infants of diabetic mothers with maternal A1c < 6% (Castro Conde et al., 
2013). Another type  of cognitive  measure that  has  been  performed in  2-month-old infant 
offspring of diabetic mothers is visual evoked potential, a test which can be performed in 
infants to  determine changes in  brain  maturation and  how  wel the  visual system is 
functioning.  One study reported that  visual evoked  potential latencies  were significantly 
longer in infants of diabetic mothers (N = 24 from T1D, 3 from T2D, and 13 from GDM 
mothers) compared to those of non-diabetic mothers (Brincioti et al., 2009). Another group 
assessed recognition  memory in  1-year-old infants  of  diabetic  mothers (N =  9  with  pre-
existing diabetes and 16 with GDM) using event-related potentials; they reported that infants 
of diabetic mothers seemed to have different event-related potential paterns which indicated 
lower 1-year cognitive development and subtle recognition memory impairments compared 
to infants of non-diabetic mothers (de Regnier et al., 2000). More specificaly, the infants of 
diabetic mothers exhibited shorter latencies to the “P2” peak compared to the control group 
(de Regnier et al., 2000). In addition, the authors observed no difference between the areas 
under the curve for the mother and stranger event-related potential for the infants of diabetic 
mothers whereas the infants of control mothers exhibited event-related potential areas under 
the curve  which  were  more  negative in response to the stranger’s  voice compared to the 
maternal voice (de Regnier et al., 2000). 
Our laboratory performed a pilot study in which they used EEGs to evaluate the 
neurodevelopment of newborn ofspring from mothers with GDM less than 48 hours after 
birth (Léveilé et al., 2018). The study included 21 neonates from non-diabetic mothers and 
25 from GDM mothers. The authors compared coherence (correlation between oscilations 
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of activity from the same brain region between the two hemispheres) and power spectral 
density (PSD) (distribution of the signal power over frequency of the signal from each 
electrode). They found that PSD was significantly lower in the left centro-occipital region 
in neonates from GDM mothers vs. non-diabetic mothers. However, these differences were 
no longer statisticaly significant when adjusted for gestational age. The authors 
hypothesized that the similarities in coherence and PSD were due to the fact that the GDM 
mothers in this study had excelent control over their blood glucose levels. This study 
highlights the importance of maintaining control of blood glucose levels in pregnancies 
complicated with GDM in order to protect fetal neurodevelopment. 
 
Long-chain polyunsaturated faty acids 
Long-chain polyunsaturated faty acids and fetal neurodevelopment 
This review  wil focus  on the role  of long chain  polyunsaturated faty acids (LC-
PUFA) in fetal neurodevelopment. Of the LC-PUFAs, there are two that are of particular 
interest in fetal neurodevelopment: Docosahexaenoic acid (DHA) and arachidonic acid (AA) 
(Figure 2). DHA is a faty acid with a 22-carbon chain with 6 double bonds. It is an omega-
3 (N-3) LC-PUFA, meaning that the first double bond is located between the third and fourth 
carbon with respect to the methyl end of the carbon chain. DHA is highly concentrated in 
brain  grey  mater and retina  phospholipids (Sastry  1985 and Innis  2007). It  plays an 
important role in synaptic plasticity, neurogenesis, and brain growth (Sastry 1985). AA is a 
faty acid with a 20-carbon chain and four double bonds. It is an omega-6 (N-6) LC-PUFA, 
meaning that the first  double  bond is located  between the sixth and seventh carbon  with 
respect to the  methyl end  of the carbon chain.  AA is found in  membrane  phospholipids 
throughout the  body. It  plays a role in  growth and is a  precursor for the  production  of 
eicosanoids which are components of immune and inflammatory pathways (Innis 2007).  
Typicaly, DHA and AA can be obtained either through diet or through the 
desaturation and elongation of essential faty acids α-linolenic acid (ALA) and linoleic acid 
(LA). The main dietary source of DHA is faty fish whereas AA is primarily found in meat, 
poultry, and eggs (Friesen & Innis, 2009). DHA and AA can be synthesized from their 
essential faty acid precursors ALA and LA, respectively, through a series of desaturation 
and elongation reactions. However, the activity of the Δ6 and Δ5 desaturase enzymes 
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involved in the formation of DHA and AA remains very low in utero (Innis 2005). The 
fetus must therefore rely on the transfer of DHA and AA from the mother through the 
placenta. During development, the fetus requires large amounts of both DHA and AA, 
particularly in the third trimester. The third trimester of gestation is an important period of 
neurodevelopment where the weight of the fetal brain increases approximately 4- to 5-fold 
(Clandinin et al., 1980). One study estimated that during the last trimester of pregnancy, 
the fetus accumulates 3660 mg of N-6 and 469 mg N-3 LC-PUFA per week (Clandinin et 
al., 1981). It was also estimated that the fetal brain accumulates 40.9 mg of N-6 and 21.8 
mg of N-3 LC-PUFA per week (Clandinin et al., 1981). A more recent study estimated that 
the daily rate of fetal accretion was 41.65 mg DHA/day and 95.25 mg AA/day at 35-40 
weeks of gestation (Kuipers et al., 2012). Given that the fetus relies on the mother to 
provide enough DHA and AA for its development, it is imperative that the mother 
consumes enough dietary DHA and AA in order to meet the needs of both the fetus and 
herself so as not to have to diminish her own faty acid reserves. 
A) Docosahexaenoic Acid (DHA 
 
 
 
 
 
 
B) Arachidonic Acid (AA) 
 
 
 
 
 
 
 
Figure 2. Structures of A) Docosahexaenoic acid (DHA) and B) Arachidonic acid (AA). 
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Figure  3. A)  Diagram  of cross-section  of a  placental  vilus.  B)  Schematic  of transfer  of 
molecules  between  maternal and fetal circulation.  Oxygen and  nutrients in the  maternal 
blood enter the fetal circulation through the syncytiotrophoblast layer. Carbon dioxide and 
waste  products exit fetal circulation and enter  maternal circulation  via the 
syncytiotrophoblast layer. Image is modified from Donely & Campling, 2016. 
 
Faty acid transfer from mother to fetus  
The transfer of faty acids such as DHA and AA from mother to fetus takes place at 
the level of the placenta. The placenta is an organ that develops during pregnancy. It serves 
as the interface between the maternal and fetal tissues and it is the sight of gas exchange, 
nutrient uptake, and waste elimination (Donnely & Campling, 2016). Between the basal 
(maternal) and chorionic (fetal) plates of the placenta, there is an intervilous space with 
tree-like vilous projections that contain fetal blood vessels (Gude et al., 2004) (Figure 3). 
The maternal blood floods the intervilous space where it can come into contact with the 
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vili. The exchange of gases, nutrients and waste between the maternal and fetal blood 
occurs at the level of the syncytium, a layer of specialized multi-nucleated 
syncytiotrophoblast cels that line the vili of the placenta (Burton & Fowden, 2015). When 
lipoproteins in the maternal blood come into contact with the microvilous membrane (the 
side of the syncytiotrophoblast cels that faces the maternal circulation), they bind to the 
lipoprotein lipase (LPL) and endothelial lipase (EL) which hydrolyze the TGs into non-
esterified faty acids (NEFA) (Islam et al., 2016). The NEFAs are then transported through 
the syncytiotrophoblast to the fetal circulation with the help of several faty acid 
transporters. While the exact mechanism of the transport of LC-PUFA across the placenta 
are not exactly known, there are several membrane proteins which are involved in the 
transport of faty acids into the syncytiotrophoblast cels, namely Faty Acid Translocase 
(FAT or CD36), Placental Plasma Membrane Faty Acid Binding Protein (pFABPpm), 
cytosolic Faty Acid Binding Protein (FABP), Major Facilitator Super Family Domain 
Containing 2a (MFSD2a), and the Faty Acid Transporter Protein (FATP) family, (Islam et 
al., 2016) (Figure 4). Once transported through the syncytiotrophoblast cels, the faty acids 
enter the fetal circulation and are transported to the fetus via the umbilical cord vein (Gude 
et al., 2004). 
 
Faty acid transfer from mother to fetus in diabetic pregnancies 
Changes in maternal lipid metabolism in diabetic pregnancies 
 Similar to the  pregnancy-induced changes in carbohydrate  metabolism, lipid 
metabolism also changes in normal pregnancies compared to the non-pregnant state. The two 
major changes in maternal lipid  metabolism  during  pregnancy are the increased 
accumulation  of lipids in  maternal tissues  during early  pregnancy and  maternal 
hyperlipidemia in later pregnancy (Herera & Ortega-Senovila, 2010). The accumulation of 
maternal  body fat in the first and second trimesters  of  gestation are largely the result  of 
hyperphagia (an abnormaly strong sense  of  hunger) and an increase in lipid synthesis 
(Herrera  &  Ortega-Senovila,  2010).  At this stage, the  maternal  metabolism is anabolic, 
meaning that the body is constructing molecules from smaler units. In contrast, maternal 
metabolism during the third trimester of pregnancy transitions to a catabolic state in which 
molecules are broken down into smaler units, in order to meet the increasing needs of the 
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fetus (Barret et al., 2014). During this period, there is an increase in adipose tissue lipolysis 
(Herrera  &  Ortega-Senovila,  2010 and  Barret et  al.,  2014).  The resulting  NEFA and 
glycerol enter into the maternal circulation and are repackaged as TGs in the liver and re-
released into the circulation in  very-low-density lipoproteins (VLDL) (Herera  &  Ortega-
Senovila,  2010).  The combination  of increased adipocyte lipolysis and  maternal insulin 
resistance increases TGs in lipoproteins and increases  VLDL,  HDL and low-density 
lipoprotein (LDL) concentration (Barret et al., 2014). Since lipoproteins are unable to cross 
the  placenta, they  must  bind to  LPL  or  EL  on the  microvilous  membrane  of the 
syncytiotrophoblast cels of the placenta in order to hydrolyze their TGs into NEFAs (Islam 
et al., 2016). These NEFAs are transported through the syncytiotrophoblast cels to enter the 
fetal circulation. 
Figure  4. Transport  of faty acids across the syncytiotrophoblast layer  of the  placenta. 
Abbreviations: LPL, lipoprotein lipase; EL, endothelial lipase; FATP, faty acid transporter 
protein;  CD36, faty acid translocase;  pFABPpm,  placental  plasma  membrane faty acid 
binding protein; FABP, faty acid binding protein. Image was inspired by Islam et al., 2016. 
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According to a review conducted by Barret and coleagues, the results of studies that 
examined  maternal lipid levels in  diabetic  pregnancies are  mixed,  with some studies 
reporting dyslipidemia and others reporting no differences (Barret et al., 2014). For pregnant 
women with T1D, it seems that those who have wel-controled T1D without other maternal 
factors (such as  metabolic syndrome, renal  disease, and  preeclampsia)  have similar 
lipoprotein levels to non-diabetic pregnant women (Barret et al., 2014). However, one study 
reported that T1D pregnant women with poor blood glucose control (A1C = 8.3%) had higher 
levels of TGs and VLDL and lower levels of HDL3 compared to T1D pregnant women with 
good blood glucose control (Merzouk et al., 2000). There are not many studies reporting data 
on  maternal lipid levels in  pregnant  women  with  T2D.  The existing studies report that 
pregnant women with T2D may have higher levels of NEFA and TGs and lower levels of 
HDL-cholesterol, while another reports no differences in maternal lipoprotein levels in T2D 
compared to  T1D,  GDM, and  non-diabetic  pregnant  women (Barret et  al.,  2014, 
Montelongo et al., 1992, Göbl et al., 2010, and Toescu et al., 2004). Finaly, pregnant women 
with GDM have been reported to have higher TG levels than non-diabetic pregnant women 
(Barret et  al.,  2014 and  Bute et  al.,  2000).  There also seems to  be  mixed findings  on 
cholesterol levels,  with some studies reporting an increase in  GDM  maternal cholesterol 
levels and others finding no change (Baret et al., 2014). 
 
Docosahexaenoic  acid  and  arachidonic  acid transfer from  mother to fetus in  diabetic 
pregnancies 
There are several studies that compare  DHA and  AA levels in the  umbilical cord 
blood in  diabetic  vs.  non-diabetic  women.  A review article  writen  by members  of  our 
laboratory summarized the findings of 12 studies which compared DHA levels in maternal 
plasma and in umbilical cord blood in diabetic vs non-diabetic pregnancies (Léveilé et al., 
2018). The authors found that  DHA levels tended to  be  higher in the  maternal  blood  but 
lower in the umbilical cord blood in pregnancies complicated by GDM or pre-existing T1D 
and T2D compared to non-diabetic pregnancies, but these results were mixed (Léveilé et 
al.,  2018).  As for  AA levels,  of the existing studies that  have reported  AA levels in the 
maternal  blood  of  diabetic  mothers,  5 reported significantly  higher  AA (Wijendran et  al., 
2000, Ortega-Senovila et al., 2009, Chen et al., 2010, Wijendran et al., 1999, and Thomas 
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et al., 2004), and 4 reported similar A levels (Prieto-Sánchez et al., 2017, Zhao et al., 2016, 
Berberovic et al., 2013 and Min et al., 2005) in diabetic mothers vs. non-diabetic mothers. 
Of the existing studies that  have reported  AA levels in the  umbilical  blood  of  diabetic 
mothers,  5 reported significantly lower levels  of  AA (Wijendran et  al., 2000,  Ortega-
Senovila et al., 2009, Min et al., 2005, Thomas et al., 2004 and Ghebremeskel et al., 2004) 
and 4 reported similar AA levels (Zhao et al., 2014, Prieto- Sánchez et al., 2017, Léveilé et 
al., 2016, and Berberovic et al. 2013) in umbilical cord blood from diabetic vs. non-diabetic 
pregnancies.  Our laboratory  previously conducted a study in  neonates from  optimaly 
controled GDM pregnancies (Léveilé et al., 2016). They compared the faty acid profile in 
the umbilical cord plasma phospholipids, NEFA, cholesterol esters, and TGs of 15 GDM and 
15 control  participants.  They found  no statisticaly significant  difference in  DHA  or  AA 
concentrations between the GDM and non-diabetic groups. The authors hypothesized that 
the similarities between DHA and AA concentrations in the umbilical cord plasma of the 
groups are the result of the GDM mothers having good control over their blood glucose levels 
so that their  A1C  was not significantly  different from the A1C  of the  mothers from the 
control group. Therefore, this study emphasizes the importance of blood glucose control in 
diabetic pregnancies.   
Since the transport of nutrients across the placenta folow a concentration gradient, 
one would expect elevated levels of DHA and AA in the maternal blood to result in similarly 
elevated levels of DHA and AA in the umbilical cord blood. However, in the case of diabetic 
pregnancies, maternal DHA and AA levels tend to be elevated whereas umbilical cord blood 
DHA and AA levels tend to be lowered. This discrepancy between maternal and umbilical 
cord blood DHA and AA levels indicates that there is a problem with the transfer of these 
faty acids from mother to fetus in diabetic pregnancies. 
 
Changes in placental faty acid transporters in diabetic pregnancies 
 To this  writer’s  knowledge, there are four studies that report  data  on the level  of 
expression  of  placental faty acid transporters in  diabetic  pregnancies (Magnusson et  al., 
2004, Radaeli et al., 2009, Prieto-Sánchez et al., 2017, and Segura et al., 2017). The first 
study (Magnusson et al., 2004) compared placenta samples from 8 T1D mothers and 8 GDM 
mothers to  8  mothers  with infants appropriately  grown-for-gestational-age (AGA).  The 
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authors found that the placenta samples from T1D diabetic mothers exhibited significantly 
higher LPL activity compared to AGA mothers (Magnusson et al., 2004). In addition, they 
found that  both  T1D and  GDM  placenta samples  had increased levels  of expression  of 
FABP1 protein compared to AGA placenta samples (Magnusson et al., 2004). The second 
study compared gene regulation in placenta samples from 6 T1D, 9 GDM, and 5 non-diabetic 
mothers (Radaeli et  al.,  2009).  They found that  both  T1D and  GDM  placentas  had 
significantly  higher levels  of  FABP4,  FABP5 and  LPL  mRNA compared to  non-diabetic 
placenta samples (Radaeli et  al.,  2009).  The third study compared the level  of  protein 
expression of several placental faty acid transporters in placenta samples from 23 women 
with diet-treated GDM, 20 women with insulin-treated GDM, and 25 non-diabetic women 
(Prieto-Sánchez et al., 2017). The authors found that placenta samples from both the diet- 
and insulin-treated  GDM  groups  had significantly lower  protein expression  of  LPL 
compared to  placentas from the  non-diabetic  group (Prieto-Sánchez et  al.,  2017). 
Furthermore,  placenta samples from  both  diet- and insulin-treated  GDM  groups  had 
significantly lower expression of MFSD2a, a transporter that is specific for DHA, compared 
to the  non-diabetic  group placentas (Prieto-Sánchez et  al.,  2017).  They also found  non-
significant increases in  FATP1,  FABP4, and  FAT/CD36 expression and  non-significant 
decreases in FATP4 expression in placentas from diet- and insulin-treated GDM compared 
to  non-diabetic controls (Prieto-Sánchez et  al.,  2017).  Finaly, the fourth study compared 
placenta gene expression of faty acid transporters in placenta samples from 18 GDM and 37 
non-diabetic women (Segura et al., 2017). The authors found that the GDM placenta samples 
had significantly  higher  FATP6 and  FAT/CD36  mRNA levels compared to  non-diabetic 
placenta samples (Segura et al., 2017). They also found significantly lower FATP1, FATP4, 
and EL mRNA levels in GDM placenta samples compared to non-diabetic placenta samples 
(Segura et al., 2017). Taken together, these studies indicate that there may be differences in 
the expression of transporters involved in faty acid transfer at the level of the placenta in 
pregnancies with T1D and GDM. 
At this time, there do not seem to be any existing studies that report the level of faty 
acid transporters in  placentas from  T2D  women.  However, there are two studies that 
examined placental faty acid transporters in overweight and obese pregnant women (Lager 
et  al.,  2016 and  Segura et  al.,  2017).  The first study found that  placenta  basal  plasma 
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membrane expression  of  FATP2  was correlated  with  maternal  BMI (Lager et  al.,  2016). 
However, they did not find any association between maternal BMI and placenta basal plasma 
membrane expression  of  FAT/CD36  or  FATP4 (Lager et  al.,  2016).  The second study 
compared  gene expression  of several faty acid transporters in  placenta samples from  28 
overweight,  30  obese, and  37  normal  weight  pregnant  women (Segura et  al.,  2017).  The 
authors reported that  placenta samples from both the  groups  who are overweight  or  have 
obesity had significantly higher mRNA levels of FAT/CD36 compared to the normal weight 
group (Segura et al., 2017). In addition, both the groups who are overweight or have obesity 
had significantly lower mRNA levels of FATP1, FATP4, FABP4, FABP7, and EL compared 
to the  normal  weight  group (Segura et  al.,  2017).  The authors also reported significantly 
higher FATP6 mRNA and lower FABP3 mRNA in the placentas from the group with obesity 
compared to the group with normal weight (Segura et al., 2017).  
Although the studies comparing placental faty acid transporters in diabetic and non-
diabetic pregnancies are scarce, they stil present evidence of disrupted regulation of faty 
acid transporters in  diabetic  placentas.  These findings could  provide insight  on  potential 
mechanisms for decreased LC-PUFA transfer from mother to fetus in diabetic pregnancies. 
 
Rationale and Hypothesis 
Diabetic pregnancies are associated with a lower transfer of DHA and AA relative to 
other faty acids from  mother to fetus.  DHA and  AA are  both important for fetal 
neurodevelopment. Ofspring of diabetic mothers tend to have poorer long-term cognitive 
outcomes compared to the background population. In the case of optimaly controled GDM, 
there is no significant diference in umbilical cord blood levels of DHA and AA between 
GDM and non-diabetic groups. In that same cohort, there was no difference in coherence 
and  PSD in  EEGs  of  neonates from  GDM  vs.  non-diabetic  mothers after adjustment for 
gestational age. These two studies emphasized the importance of blood glucose control in 
diabetic pregnancies. In the case of pregnancies complicated by pre-existing T1D or T2D, 
the diabetic condition is present prior to conception and it may be more difficult to control 
blood glucose levels compared to GDM patients. Furthermore, pregnant women with T1D 
and T2D are more prone to hypoglycemic and hyperglycemic episodes throughout gestation. 
Therefore,  we  hypothesize that  pre-existing  T1D and  T2D  during  pregnancy lowers the 
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transfer of DHA and AA from mother to fetus which results in lower neurodevelopment of 
the neonate. 
 
Objectives 
Objective #1 
Evaluate whether the concentration and relative percentage of DHA and AA are diferent in 
the maternal plasma, placenta, and umbilical cord serum/whole blood of diabetic and non-
diabetic mothers. 
 
Objective #2 
Evaluate PSD and coherence in EEGs of newborns from diabetic and non-diabetic mothers 
at 2 time points (24-48 hours after birth and at 48 weeks post-amenorrhea)
 
2MATERIALS AND METHODS 
 
Population 
Two groups of pregnant women (aged 18-40 years, singleton pregnancy) were 
recruited at the Centre hospitalier universitaire de Sherbrooke between 2017 and 2020. The 
first group (n = 7) was composed of pregnant women with T1D or T2D which was 
diagnosed prior pregnancy. The second group (n = 26) was composed of pregnant women 
without diabetes during pregnancy. The participants were recruited between 24-28 weeks 
of gestation. Exclusion criteria included twin pregnancy, current or past smoking, curent 
or past alcohol/drug abuse, placental anomalies, premature delivery, uncontroled 
endocrine, liver, or renal problems, cancer, consumption of DHA supplements during 
pregnancy, or any medical condition or medication affecting lipid metabolism. 
 
Ethics Statement 
The study was approved by the Ethics Research Commitee of the Centre intégré 
universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de 
Sherbrooke. During recruitment, the participants signed a consent form for both themselves 
and their baby. Consent was free and informed and participants were free to withdraw from 
the study or withdraw their baby from the study without explanation at any time of the 
protocol.  
 
Anthropometric data colection and blood sampling 
Maternal weight was measured at hospital admission prior to delivery and BMI was 
calculated. Maternal blood samples were colected at the hospital admission prior to 
delivery to measure A1C. An additional 3 mL of blood was colected from the mothers, 
centrifuged, aliquoted, and stored at -80 °C for faty acid profiling at a later date. After 
delivery, the neonate’s weight, length, head circumference, and APGAR score were 
recorded. The APGAR score is a score from 0-10 which indicates the health of the 
newborn baby. It is comprised of 5 components: colour, heart rate, reflexes, muscle tone, 
and respiration (American Academy of Pediatrics, 2015). A 5-minute APGAR score of 0-3 
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is low, 4-6 is moderately abnormal, and 7-10 is reassuring. In addition, 6 mL of venous 
umbilical cord blood was colected. Half of the venous umbilical cord blood was aliquoted 
and stored at -80 °C as whole blood for faty acid profiling at a later date. The other 3 mL 
of venous umbilical cord blood was left to clot at room temperature and the remaining 
serum was colected, aliquoted, and stored at -80 °C for faty acid profiling at a later date. 
Two placenta samples (one from the maternal/decidual region and the other from the 
fetal/chorionic region of the placenta) of approximately 1 cm3 in size were colected and 
stored at -80 °C for faty acid profiling at a later date. 
 
Blood and placenta sample analyses 
Maternal A1C was measured using high-performance liquid chromatography (Bio-
Rad VARIANT) in the Biochemistry laboratory of the Centre Hospitalier Universitaire de 
Sherbrooke. Faty acid profiling of the maternal plasma, umbilical cord serum, umbilical 
cord whole blood, maternal placenta, and fetal placenta were performed as described in the 
folowing sections. 
 
Maternal plasma and umbilical cord serum total lipid extraction 
Total lipids were extracted from maternal plasma and umbilical cord serum using 
the Folch extraction method (Folch et al. 1957). Briefly, 250 µL plasma or umbilical cord 
serum were combined with 10 mL 2:1 chloroform-methanol (v/v). A known quantity of 
internal standard (triheptadecanoin, Nu-Chek Prep, Inc.) was added to the mixture in order 
to later quantify the concentration of each faty acid in the sample. The aim was to add an 
amount of internal standard that corresponded to approximately 10% of the total faty acids 
in the sample, but naturaly the actual relative percentage of internal standard varied as the 
total faty acids varied between each sample. Once the preparation rested for one hour in 
the dark, 2 mL 0.9% saline was added and the tubes were centrifuged at 1500 rpm for 10 
minutes in order to separate the organic and aqueous phases. The organic phase (containing 
chloroform and lipids) was colected. 
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Umbilical cord whole blood total lipid extraction 
The procedure for total lipid extraction from whole blood was adapted from a 
previously described method (Rose & Oklander, 1965). Briefly, 250 µL thawed whole 
blood was combined with 250 µL water to lyse the erythrocytes. While vortexing, 2.5 mL 
of isopropanol was slowly added to the test tube drop-by-drop in order to avoid clumping 
of the blood sample. Once the isopropanol was added, the tube was removed from the 
vortex and internal standard (triheptadecanoin, Nu-Chek Prep, Inc.) and 5 mL of 
chloroform were added. The tube was briefly shaken and then left to rest in the dark for 
one hour. After the rest period, 2 mL 0.9% saline was added and the tubes were centrifuged 
at 1800 rpm for 10 minutes in order to separate the organic and aqueous phases. The 
organic phase (containing chloroform and lipids) was colected. 
 
Placenta total lipid extraction 
Total lipids were extracted using a similar methodology to that of the maternal 
plasma and umbilical cord serum with some modifications. Since the placenta is a tissue, it 
first needed to be processed into powder before proceeding with the Folch extraction. After 
colection, the placenta pieces were frozen at -80 ℃. While on dry ice, the placenta tissue 
samples were ground into a fine homogenous powder using a BioPulverizer tissue 
homogenizer (Biospec Products). The placenta powder was colected in 1.5 mL Eppendorf 
tubes and was subsequently stored at -80 ℃	until extraction. For the extraction, 
approximately 100 mg of placenta powder, 17:0 PC internal standard (1,2-
diheptadecanoyl-sn-glycero-3-phosphocholine, Avanti) and 5 mL 2:1 chloroform-methanol 
(v/v) were combined in a 7 mL poter tissue homogenizer (Kontes Glass Co.). The tissue 
homogenizer was then used to combine the mixture of placenta powder with the internal 
standard and chloroform-methanol until the placenta powder was dissolved into the 
solution. The mixture was then poured into a 15 mL test tube. An additional 5 mL of 2:1 
chloroform-methanol (v/v) was added to the poter in order to recuperate any placenta 
powder remnants, and then poured into the same 15 mL test tube. The contents of the test 
tube were briefly shaken and then left to rest in the dark for one hour. After the resting 
period, 2 mL 0.9% saline was added and the tubes were centrifuged at 1500 rpm for 10 
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minutes in order to separate the organic and aqueous phases. The organic phase (containing 
chloroform and lipids) was colected. 
 
Faty acid profiling 
After extraction from the different biological samples, the organic phase, consisting 
of chloroform and extracted total lipids, was evaporated using a nitrogen evaporator. The 
extracted lipids then underwent saponification: 3 mL KOH-methanol were added to the 
tubes which were subsequently capped under nitrogen and heated at 90 ℃ for one hour. 
This reaction breaks the ester bonds of the cholesterol esters and TGs and the K+ from the 
KOH interacts with the free O- on the carboxyl end of the faty acid, resulting in faty acid 
salts. This step also serves as a method to remove cholesterol, a contaminant for the gas 
chromatography column, from the sample. Subsequent to the heating and a brief 15-minute 
rest period in the dark at room temperature, 2 mL 0.9% saline and 5 mL hexane were added 
to the tubes. The tubes were shaken and then centrifuged at 1500 rpm for 4 minutes in 
order to separate the organic and aqueous phase. The organic phase (consisting of hexane 
and cholesterol) was removed and discarded. The remaining aqueous phase (methanol, 
saline and faty acid salts) was combined with 300 µL concentrated hydrochloric acid 
(37%) and 5 mL hexane. The addition of concentrated hydrochloric acid serves to 
protonate the faty acid salts, resulting in free faty acids (FFAs). The tubes were then 
shaken and centrifuged at 1500 rpm for 4 minutes to separate the organic and aqueous 
phases. At this step, the FFAs were located in the organic hexane layer since they were no 
longer polar. The organic layer (hexane + FFAs) was colected, transferred to new tubes 
and evaporated using the nitrogen evaporator. The FFAs were trans-methylated through a 
process caled methylation: 3 mL BF3-methanol were added to the test tubes containing 
FFAs which were subsequently capped under nitrogen and heated at 90 ℃	for 30 minutes. 
During this reaction, a methyl group is added to the carboxyl end of the faty acids, 
resulting in faty acid methyl esters (FAMEs). The addition of a methyl group to the faty 
acid increases its volatility and decreases its affinity for the column in gas chromatography. 
Folowing a rest period of 15 minutes in the dark at room temperature, 2 mL 0.9% saline 
and 5 mL hexane were added to the tubes which were then shaken and centrifuged at 1500 
rpm for 4 minutes to separate the organic and aqueous phases. The organic hexane layer 
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(consisting of hexane and FAMEs) was colected and then evaporated using the nitrogen 
evaporator. Hexane was then added to the FAMEs so that they had a final concentration of 
approximately 0.3 mg/mL. The samples were then transferred to glass vials to prepare for 
gas chromatography. 
 
Gas chromatography 
FAMEs were analyzed by a gas chromatograph (model 6890, Agilent) equipped 
with a 50 m fused capilary column (SGE; 0.22 mm inner diameter, 0.25 µm film 
thickness). Splitless mode injection and flame ionization detection were performed at 
250°C and 260°C, respectively. 1 µL injections of FAMEs were made. The oven 
temperature program began at 50 °C for 2 minutes, increased to 170°C at a rate of 
20°C/minute and held for 10 minutes, increased to 195°C at a rate of 10°C/minute and held 
for 35 minutes, and increased to 220°C at a rate of 20°C/minute and held for 5 minutes. 
The inlet pressure of the carrier gas (helium) was 107 kPa at 50°C. The total run time was 
61.75 minutes. During this process, the FAMEs are vaporized into a gas and are pushed 
through the column by the carrier gas helium. They then exit the column where they are 
burned by a hydrogen-fueled flame. The resulting ions then pass between two charged 
plates and produce an electric signal which is measured by the detector. The resulting data 
is a chromatogram, which consists of a series of peaks that correspond to each faty acid. 
The area of the internal standard peak is used to calculate the concentration of each faty 
acid. Faty acids are identified based on their retention time, or the time it takes for the 
FAME to exit the column. Specific retention times are identified using a mix of known 
FAMEs. There are two factors that influence the time is takes for FAMEs to elute from the 
column: their boiling point and their affinity for the column. FAMEs with shorter 
hydrocarbon chains are vaporized before FAMEs with longer hydrocarbon chains due to 
their lower boiling point. For FAMEs with hydrocarbon chains of the same length, they are 
further separated in the column due to their differing affinities for the column. Since the 
column is non-polar, FAMEs with less polarity wil have more affinity for the column and 
therefore wil stay in the column for longer. FAMEs with double bonds are less polar, 
causing them to exit the column at a later time than their saturated counterparts.  
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Figure 5. Schematic representation of EEG montage (adapted from Léveilé et al., 2018). 
 
EEG montage and data acquisition 
EEGs were performed in newborns at two time points: 24-48 hours after birth and 
at 48 weeks post-amenorrhea. EEG montage and data acquisition were carried out using 
the methods described in Léveilé et al., 2018. Briefly, the EEG data was recorded using a 
14-channel bi-polar montage based on the 10-20 System (Grass Technologies). The 
montage, pictured in Figure 5, consisted of the folowing channels: left and right fronto-
temporal channels (Fp1-T3; Fp2-T4), left and right fronto-central channels (Fp1-C3; Fp2-C4), 
left and right central channels (C3-Cz; C4-Cz), left and right centro-temporal channels (C3-
T3; C4-T4), left and right temporo-central channels (T3-Cz; T4-Cz), left and right centro-
occipital channels (C3-O1; C4-O2), and left and right temporo-occipital channels (T3-O1; T4-
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O2). Silver-silver chloride electrodes were secured onto the infant’s scalp using conductive 
water-soluble fixative paste and adhesive tape. Heart rate and respiratory movements were 
measured using two electrocardiogram electrodes and a thoracic respiratory band, 
respectively. EEG signal acquisition was performed for 12.5 minutes at a 200 Hz sampling 
rate on awake infants. The EEG data was processed using in-house Matlab scripts 
(Mathworks). The continuous EEG signal was converted into z-scores and divided into 
non-overlapping 5 second windows. Windows with z-scores greater than 10 were removed 
because they were considered to be movement artifacts. Power spectral density was 
calculated for each electrode pair using Welchs’ approach on Matlab (‘pwelch.m’). 
Coherence between channels in the left and right hemisphere was computer using 
‘mscohere.m’ in Matlab. 
 
Statistical analysis 
Normal distribution was evaluated using the Shapiro-Wilk normality test and 
variances were compared using the F test. Chi-square tests were used to compare 
proportions between groups. Mean DHA and AA relative percentage and concentration 
were compared between groups using either unpaired t-tests, unpaired t-tests with Welch’s 
correction, or the Mann Whitney test depending on the normality of the distributions and 
the variances of the groups. Mean coherence and mean PSD were compared between 
groups using the Mann Whitney test. Al tests were performed using GraphPad Prism 
software, Version 7.0c (GraphPad Software, Inc.). Two-tailed p-value < 0.05 was 
considered statisticaly significant 
 
 
 
 
 
 
 
 
 
 
 
 
 
3RESULTS 
 
 
Characteristics of mothers and newborns 
Twenty-six control and seven diabetic mothers were recruited. Of the seven 
diabetic mothers recruited, two had T1D and five had T2D. Age was similar, but body 
mass index (BMI) and A1C differed between groups (Table 1). The mean ages of the 
control and diabetic groups were 29.4 ± 2.7 and 30.6 ± 7.8 years, respectively (P = 0.704). 
BMI close to delivery was higher in the diabetic group compared to the control group (34.6 
± 11.3 vs. 23.5 ± 2.9 kg/m2; P = 0.0004). Al participants in the diabetic group were either 
overweight (n = 3) or obese (n = 4) according to their BMI status. The mean BMI was 26.2 
± 1.3 kg/m2 for participants with T1D and 38.0 ± 11.9 kg/m2 for participants with T2D. 
The majority of participants in the control group were in the healthy weight range (n = 16) 
while others were in the overweight (n = 6) and obese ranges (n = 1). A1C was higher in 
diabetic mothers compared to control mothers (6.1 ± 0.5 vs. 5.1 ± 0.3 %; P < 0.0001).  
The sex ratio, birth weight, length, head circumference, and APGAR score at 1 and 
5 minutes of the newborns were similar between the two groups (Table 1). The sex ratio of 
the neonates was 5 males/2 females and 15 males/11 females in the diabetic and control 
group, respectively (P = 0.822). Birth weight was 3641 ± 488 grams in the diabetic group 
and 3432 ± 370 grams in the control group (P = 0.224). Three infants from the diabetic 
group were LGA, whereas the control group had one infant who was LGA and one infant 
who was smal for gestational age. Two neonates from the control group and one neonate 
from the diabetic group weighed ≥ 4000 grams at birth, meaning they fal under the 
category of fetal macrosomia. Head circumference was similar between the diabetic and 
control groups (51.0 ± 3.0 cm vs. 50.9 ± 2.5 cm; P = 0.579). APGAR scores at 1 minute 
(6.6 ± 3.7 vs. 8.5 ± 0.9; P = 0.542) and at 5 minutes (8.3 ± 2.1 vs. 9.2 ± 0.9; P = 0.252) 
were not statisticaly diferent between the diabetic and control groups. Al neonates in the 
control group reached a score between 7 and 10 for the 5-minute APGAR score. For the 
diabetic group, there was one neonate that had a 5-minute APGAR score of 4, but this 
neonate’s APGAR score increased to 9 by 10 minutes. The only diference in the newborn 
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characteristics between the two groups was gestational age. The gestational age of the 
neonates from the diabetic group was significantly lower than the neonates from the control 
group (38.1 ± 0.9 vs. 40.0 ± 1.1 weeks; P = 0.0006). Al neonates were born at 37 weeks or 
later, meaning none of the neonates were born premature. 
Table 1 
Characteristics of mothers and newborns. 
 
n 
Controls 
(n = 26) 
n 
Diabetics 
(n = 7) 
P value 
Maternal characteristics      
Type of diabetes 26 N/A 7 2 T1D; 5 T2D  
Age (years) 26 29.4 ± 2.7 7 30.6 ± 7.8 0.704 
BMI (kg/m2) 23 23.5 ± 2.9 7 34.6 ± 11.3 <0.001 
A1C at delivery (%) 25 5.1 ± 0.3 7 6.1 ± 0.5 <0.001 
      
Newborn characteristics 26  7   
Sex ratio (male/female), n 26 15/11 7 5/2 0.822 
Gestational age (weeks) 26 40.0 ± 1.1 7 38.1 ± 0.9 <0.001 
Birth weight (g) 26 3432 ± 370 7 3641 ± 488 0.224 
Length (cm) 26 50.9 ± 2.5 7 51.0 ± 3.0 0.938 
Head circumference (cm) 26 34.4 ± 1.1 7 34.7 ± 1.7 0.579 
APGAR score (1 min) 26 8.5 ± 0.9 7 6.6 ± 3.7 0.542 
APGAR score (5 min) 26 9.2 ± 0.9 7 8.3 ± 2.1 0.252 
Abbreviations: T1D, type 1 diabetes; T2D, type 2 diabetes; BMI, body mass index; 
Statistical differences between group means were determined using either independent t-
tests or Mann Whitney tests, as appropriate. Statistical differences between proportions 
were computed using Chi-square test. Statistical significance is denoted by P value in bold. 
Data is presented as mean ± standard deviation. 
 
Fatty acid profile: Docosahexaenoic acid and arachidonic acid 
The DHA and AA relative percentage and concentrations in maternal plasma, 
umbilical cord serum, umbilical cord whole blood, maternal placenta, and fetal placenta 
total lipids wil be discussed in the folowing sections (Figure 6). The complete faty acid 
profile for each biological sample can be found in the supplementary section (Annex 1-5). 
 
Maternal plasma total lipids 
The mean relative percentage of DHA in the maternal plasma did not differ 
between the diabetic and control groups (1.41 ± 0.09% vs. 1.30 ± 0.08%; P = 0.473). 
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Similarly, there was no statisticaly significant difference in maternal plasma DHA 
concentration between the diabetic and control groups (6.1 ± 0.6 mg/dL vs. 6.1 ± 0.4 
mg/dL; P = 0.932). 
 
Figure 6. (A) DHA relative percentage, (B) DHA concentration, (C) AA relative 
percentage, and (D) AA concentration in maternal plasma, umbilical cord serum, umbilical 
cord whole blood, maternal placenta, and fetal placenta total lipids. Each dark grey circle 
represents an individual from the control group and each light grey square represents an 
individual from the diabetic group. The mean and standard error of the mean are denoted 
by the horizontal lines and the error bars. Statisticaly significant differences between 
groups (P < 0.05) are denoted by a “*”. Abbreviations: DHA, docosahexaenoic acid; AA, 
arachidonic acid; C, control; D, diabetic. 
 
The mean relative percentage of AA in maternal plasma total lipids was 19% higher 
in diabetics compared to non-diabetics (6.04 ± 0.61% vs. 5.06 ± 0.19%; P = 0.049). 
Maternal plasma AA concentration was not statisticaly different between the diabetic and 
control groups (26.0 ± 3.3 mg/dL vs. 24.1 ± 1.3 mg/dL; P = 0.526) 
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Umbilical cord serum total lipids 
The mean relative percentage of DHA in umbilical cord serum total lipids did not 
differ significantly between the diabetic and control groups (3.69 ± 0.37% vs. 3.97 ± 
0.19%; P = 0.484). The mean umbilical cord serum concentration of DHA was ~19% 
lower in the diabetic group compared to the non-diabetic group, but this result was not 
statisticaly significant (3.5 ± 0.3 mg/dL vs. 4.3 ± 0.3 mg/dL; 0.146; P = 0.146). 
Umbilical cord serum AA mean relative percentage was not statisticaly different 
between the diabetic and control groups (13.47 ± 0.90% vs. 14.23 ± 0.37%; P = 0.368). 
However, mean AA concentration was ~16% lower in diabetic compared to non-diabetic 
cord serum (12.9 ± 0.7 mg/dL vs. 15.3 ± 0.7 mg/dL; P = 0.019). 
 
Umbilical cord whole blood total lipids 
 Mean DHA relative percentage in umbilical cord whole blood total lipids was not 
statisticaly different between the diabetic and non-diabetic groups (6.24 ± 0.44% vs. 6.47 
± 0.38%; P = 0.763). Similarly, umbilical cord whole blood mean DHA concentration did 
not differ between the diabetic and non-diabetic groups (10.5 ± 1.2 mg/dL vs. 10.6 ± 1.0 
mg/dL; P = 0.729). 
 Mean AA relative percentage in umbilical cord whole blood total lipids was similar 
between the diabetic and control groups (22.36 ± 1.00% vs. 21.90 ± 0.58%; P = 0.706). In 
addition, mean AA concentration was also similar in the umbilical cord whole blood of the 
diabetic and control groups (37.6 ± 3.8 mg/dL vs. 35.1 ± 2.4; P = 0.622). 
 
Maternal placenta total lipids 
 Mean DHA relative percentage was not statisticaly different between the diabetic 
and control groups (4.82 ± 0.37% vs. 4.51 ± 0.17%; P = 0.427). Mean DHA concentration 
was also not statisticaly different in the maternal placenta of the diabetic versus the control 
group (400 ± 39 µg/g vs. 444 ± 32 µg/g; P = 0.696). 
 Similarly, there were no significant diferences in AA levels between the two 
groups. Mean AA relative percentage was not statisticaly different in the maternal placenta 
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from the diabetic group compared to the non-diabetic group (25.40 ± 0.48% vs. 25.40 ± 
0.44; P = 0.999). Maternal placenta mean AA concentration was also not statisticaly 
different between the diabetic and control groups (2206 ± 331 µg/g vs. 2543 ± 180 µg/g; P 
= 0.386). 
 
Fetal placenta total lipids 
 Relative percentage of DHA in fetal placenta tissue was not statisticaly different 
between the diabetic and non-diabetic groups (3.69 ± 0.14% ± 3.65 ± 0.14%; P = 0.886). 
Fetal placenta DHA concentrations were also not significantly different between the 
diabetic and control group (276 ± 14 µg/g vs. 292 ± 15 µg/g; P = 0.602). 
 Fetal placenta AA relative percentage was not statisticaly different between the 
diabetic and control groups (22.69 ± 0.28% vs. 22.28 ± 0.35%; P = 0.370). In addition, 
there was no statisticaly significant difference in fetal placenta AA concentrations in the 
diabetic versus the non-diabetic groups (1713 ± 116 µg/g vs. 1808 ± 91 µg/g; P = 0.607). 
 
Electroencephalography 
Of the 26 newborns from the control group, 22 completed the first EEG and 17 
completed the second EEG. Of the 7 newborns from the diabetic group, 4 completed the 
first EEG and 3 completed the second EEG. 
 
Coherence 
Coherence represents a correlation coefficient value between the EEG activity of 
the same brain region in the left and right hemisphere. The mean coherence data between 
various brain regions at 24-48 hours after birth (T0) and 48 weeks post-amenorrhea (T2) is 
displayed in ful in Supplementary Table 6. For the purpose of brevity and clarity, only the 
results that differed between groups wil be discussed in this section.  
Figure 7 shows the mean coherence data in the beta frequency range (13.0 – 20.0 
Hz) between various brain regions. There were a number of differences in mean coherence 
between T0 and T2 within groups. For instance, the control group had a ~5-6% lower mean 
coherence at T2 compared to T0 in the centro-occipital, temporo-occipital, and temporo-
central channels (P = 0.009, 0.004, and 0.036, respectively). There was also a trend in the 
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control group for higher mean coherence at T2 compared T0 in the fronto-temporal 
channels, but this trend was not statisticaly significant (P = 0.091). The diabetic group also 
had some trends for diferences in mean coherence between T2 and T0; mean coherence 
was 5.5% higher in the fronto-central channel and 4.5% lower in the temporo-occipital 
channel at T2 compared to T0, but these trends were not statisticaly significant (P = 0.057 
for both). There were also some diferences between the diabetic and control group at T0. 
For example, mean coherence in the fronto-temporal regions at T0 was higher in the 
diabetic compared to non-diabetic group (0.398 ± 0.010 vs. 0.378 ± 0.004; P = 0.031). 
Similarly, there were also some trends towards higher mean coherence in the diabetic 
group at T0 compared to the control group in the fronto-central and central channels, but 
these trends were not statisticaly significant (P = 0.069 and 0.082, respectively). There 
were no diferences in mean coherence at T2 between the diabetic and non-diabetic group. 
Figure 7. Mean coherence for the beta frequency range (13.0 – 20.0 Hz) in the centro-
occipital (C3-O1 / C4-O2), fronto-central (Fp1-C3 / Fp2-C4), fronto-temporal (T3-Fp1 / 
Fp2-T4), temporo-occipital (T3-O1 / T4-O2), temporo-central (T3-Cz / T2-Cz) and central 
(C3-Cz / Cz-C4) channels. T0 refers to 24-48 hours after birth and T2 refers to 48 weeks 
post-amenorrhea. Statisticaly significant diferences (P < 0.05) are denoted by “*”. P 
values < 0.1 are denoted represented by “.”. Data are presented as mean ± standard error of 
the mean. 
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Figure 8. Mean power spectral density (PSD) for the (A) Delta (0 – 3.4 Hz) and (B) Theta 
(3.5 – 7.4 Hz) frequency ranges in the left centro-occipital (C3-O1), left temporo-occipital 
(T3-O1), right centro-occipital (C4-O2), and right temporo-occipital (T4-O2) channels. T0 
refers to 24-48 hours after birth and T2 refers to 48 weeks post-amenorrhea. Statisticaly 
significant differences (P < 0.05) are denoted by “*”. P values < 0.1 are denoted 
represented by “.”. Data are presented as mean ± standard error of the mean. 
 
Power spectral density 
As previously explained, PSD is the power of the EEG signal as a function of 
frequency, per unit frequency. The mean PSD in al the electrode channels at 24-48 hours 
after birth and at 48 weeks post-amenorrhea can be found in Supplementary Table 7. 
Similar to the coherence section, only the PSD data that showed the most differences 
between timepoints or between groups wil be discussed in this section. 
Figure 8 summarizes the mean PSD in the delta and theta frequencies in the left and 
right centro-occipital and temporo-occipital channels at T0 and T2. For the delta frequency 
(Figure 8.A), both the control and the diabetic groups had a higher mean PSD at T2 
compared to T0 in the left and right centro-occipital and temporo-occipital regions. 
Differences in mean PSD between T2 and T0 were statisticaly significant for the control 
group (P < 0.0001 for the left and right centro-occipital and left and right temporo-occipital 
regions) but not statisticaly significant for the diabetic group (P = 0.057 for the left and 
right centro-occipital and left and right temporo-occipital regions). This same patern was 
also echoed in the theta frequency range. The control group had a higher mean PSD at T2 
compared to T0 in the left centro-occipital (P < 0.001), left temporo-occipital (P < 0.001), 
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right centro-occipital (P < 0.0001), and the right temporo-occipital (P = 0.001) channels. 
The diabetic group also had a trend towards higher mean PSD at T2 compared to T0 in the 
same channels (P = 0.057 for al). PSD did not differ significantly between the diabetic and 
control groups at T0 nor at T2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4DISCUSSION 
 
 
Characteristics of mothers and newborns 
 Of the maternal characteristics that were measured, only two differed between the 
diabetic and non-diabetic groups: BMI and A1C at delivery. As previously stated, BMI was 
much higher in the diabetic mothers compared to the non-diabetic mothers. This is 
unsurprising given that approximately 80-90% of individuals with T2D are overweight or 
obese (Wing, 2000). In addition, obesity is also becoming more prevalent in individuals 
with T1D (Conway et al., 2010). A1C at delivery was also significantly higher in diabetic 
mothers compared to non-diabetic mothers. According to the 2018 Diabetes Canada 
Clinical Practice Guidelines Expert Commitee, women with pre-existing T1D and T2D 
during pregnancy should aim for an A1C level of ≤ 6.5% (idealy ≤ 6.1%) during 
pregnancy (Feig et al., 2018). In the case of the diabetic participants in this study, four out 
of seven participants had A1C levels ≤ 6.1% and two out of seven had A1C levels ≤ 6.5%. 
One of the diabetic participants had an A1C level of 6.7% which is higher than 
recommended. Overal, it can be said that the diabetic participants in this study had 
adequate control of their blood glucose levels, however their A1C levels were stil 
significantly higher than the non-diabetic participants. In terms of the newborn 
characteristics, only gestational age difered significantly between the groups. On average, 
neonates from diabetic mothers were approximately two weeks younger than neonates 
from the non-diabetic mothers at birth. This is also unsurprising given the use of induction 
of labour to reduce the risks associated with fetal macrosomia in diabetic pregnancies 
(Mozurkewich et al., 2009). 
 
Fatty acid transfer from mother to fetus 
Maternal plasma DHA and AA levels 
 Both the relative percentage and the concentration of DHA did not differ 
significantly between in the maternal plasma total lipids of the diabetic and the non-
diabetic groups. To this writer’s knowledge, there are three other studies that have reported 
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DHA levels in pregnant women with pre-existing T1D and T2D (Berberovic et al., 2013, 
Min et al., 2005, and Min et al., 2014). The first study (Berberovic et al., 2013) reported a 
55% higher concentration of DHA in maternal vein serum total lipids of T1D pregnant 
women (N = 32) compared to non-diabetic pregnant women (N = 31). However, 
Berberovic and coleagues did not find any statisticaly significant diferences in relative 
percentage of DHA in the maternal vein serum total lipids of the T1D compared to the non-
diabetic group. The second study (Min et al., 2005) assessed the relative percentage of 
DHA in the maternal plasma TG and choline phosphoglycerides and in maternal red blood 
cel (RBC) choline phosphoglycerides and ethanolamine phosphoglycerides of pregnant 
women with T1D (N = 32), T2D (N = 17), and without diabetes (N = 39). The authors 
observed no statisticaly significant diference in plasma TG relative percentage of DHA 
between the T1D, T2D and non-diabetic groups (Min et al., 2005). However, relative 
percentage of DHA was approximately 40% lower in the plasma choline 
phosphoglycerides of the T1D group compared to the non-diabetic group (Min et al., 
2005). They also observed a similar trend in the T2D plasma choline phosphoglycerides, 
but this diference was not statisticaly significant (Min et al., 2005). They also found 
significantly lower relative percentage of DHA in the RBC choline phosphoglycerides of 
both T1D and T2D compared to non-diabetic pregnant women (Min et al., 2005). Relative 
percentage of DHA was also significantly lower in the RBC ethanolamine 
phosphoglycerides of the T1D mothers compared to the non-diabetic mothers (Min et al., 
2005). The T2D mothers also had a lower percentage of DHA in their RBC ethanolamine 
phosphoglycerides compared to non-diabetic mothers, but this difference was not 
statisticaly significant (Min et al., 2005). The final study (Min et al., 2014) compared 
DHA relative percentage in the maternal plasma choline phosphoglycerides and in the 
maternal red RBC choline phosphoglycerides and ethanolamine phosphoglycerides of 
pregnant women with T2D (N = 30) and without diabetes (N = 30). They found no 
significant differences in DHA relative percentage in the plasma choline 
phosphoglycerides, RBC choline phosphoglycerides, or the ethanolamine 
phosphoglycerides of T2D compared to non-diabetic pregnant women in the third trimester 
(Min et al., 2014). In summary, these three studies tended to find lower relative percentage 
of DHA in the maternal plasma choline phosphoglycerides, RBC choline 
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phosphoglycerides, and RBC ethanolamine phosphoglycerides compared to the non-
diabetic groups (Berberovic et al., 2013, Min et al., 2005, and Min et al., 2014). They also 
reported no difference between relative percentage of DHA in serum total lipids of T1D 
women and in plasma TG of T1D and T2D women compared to non-diabetic group 
(Berberovic et al., 2013, Min et al., 2005). Finaly, one study reported higher DHA 
concentration in serum total lipids of T1D mothers compared to non-diabetic mothers 
(Berberovic et al., 2013). 
When comparing findings between these previous studies and the current study, it is 
important to consider that they do not al report DHA levels in the same blood pool. For 
instance, both the Berberovic et al. study and the current study reported DHA levels in 
plasma or serum total lipids. Serum and plasma are similar; the main difference between 
them is that plasma is colected prior to cloting and therefore stil contains cloting agents 
whereas serum is colected after cloting and therefore does not contain cloting agents. 
Plasma/serum total lipids are composed of approximately 49% TGs, 24% phospholipids, 
and 16% cholesteryl esters (Brenna et al., 2018). The faty acid composition of the TG pool 
in particular is greatly influenced by recent food intake and therefore can vary greatly 
between individuals (Brenna et al., 2018). Since a large proportion of plasma/serum total 
lipids are in the TG form, the faty acids in total lipids can also vary depending on the 
individual’s recent food consumption. Plasma total lipids are logisticaly advantageous 
since plasma samples are routinely colected in clinical setings and their faty acids are 
relatively stable over time (Brenna et al., 2018). On the other hand, the Min et al. 2005 and 
Min et al., 2014 studies reported DHA levels in plasma choline phosphoglycerides and in 
RBC choline phosphoglycerides and ethanolamine phosphoglycerides. Plasma choline 
phosphoglycerides are part of the plasma phospholipid pool. Since this type of sample does 
not contain TGs, it is not as susceptible to changes in faty acid levels based on recent food 
consumption and is instead thought to be more representative of the faty acid levels in cel 
membranes (Brenna et al., 2018). Finaly, the RBC choline and ethanolamine 
phosphoglycerides are part of the RBC phospholipid pool. They represent part of the 
phospholipids that compose the phospholipid bilayer of the RBCs. The average circulatory 
lifespan of RBCs is approximately 120 days compared to 2 weeks for plasma 
phospholipids and within hours for TGs. Due to the longer lifespan of RBCs, their faty 
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acid composition is thought to be more reflective of long-term dietary faty acid intake 
(Brenna et al., 2018). When considering the diferent blood pools in the previously 
mentioned studies, it seems that a greater relative percentage of DHA is present in RBC 
choline and ethanolamine phosphoglycerides and in plasma choline phosphoglycerides 
compared to plasma TG and plasma/serum total lipids. Previous studies reported 
significant differences in relative percentage of DHA in the diabetic groups in these RBC 
choline and ethanolamine phosphoglycerides and in plasma choline phosphoglycerides 
pools (Min et al., 2005 and Min et al., 2014). However, relative percentage of DHA does 
not seem to difer in plasma TG or in serum total lipids of diabetic mothers compared to 
control mothers (Berberovic et al., 2013 and Min et al., 2005). Since plasma and serum 
total lipids are composed of a greater proportion of TGs relative to phospholipids, perhaps 
any changes in relative percentage in DHA in the phospholipid fraction of total lipids may 
be masked by the larger proportion of TGs present. This could potentialy explain why we 
did not see any significant diference in the relative percentage of DHA in the maternal 
plasma total lipids of diabetic mothers compared to non-diabetic mothers. Moreover, since 
our study used plasma total lipids, our results could have been influenced by the 
participants’ food intake at the time of sample colection. That being said, our results for 
relative percentage of DHA in the maternal plasma total lipids are in line with the other 
studies that reported DHA levels in similar blood pools (Berberovic et al., 2013 and Min et 
al., 2005). The main difference between the current study and previous studies is in the 
DHA concentration. Of the previously discussed studies, only the Berberovic et al., 2013 
study reported maternal DHA concentrations. As previously mentioned, they found 
significantly higher concentration of DHA in the plasma total lipids of T1D pregnant 
women compared to non-diabetic pregnant women (Berberovic et al., 2013). This higher 
DHA concentration was not present in our diabetic group compared to the non-diabetic 
group. It seems that in the Berberovic study, the relative percentage of DHA in the plasma 
total lipids was the same between groups, but the total concentration of faty acids overal 
was higher in the T1D group compared to the control group (Berberovic et al., 2013). As a 
result, they observed a higher concentration of plasma total lipids DHA. In the current 
study, neither the total concentration of plasma total lipids faty acids nor the relative 
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percentage of DHA differed significantly between the diabetic and non-diabetic groups, 
and therefore we did not see a diference in plasma total lipid DHA concentration. 
As for AA, we observed a significantly higher relative percentage of AA in the 
plasma total lipids of diabetic mothers compared to non-diabetic mothers. However, we did 
not observe a statisticaly significant difference in plasma total lipid AA concentration in 
the diabetic and non-diabetic groups. To this writer’s knowledge, there are only two studies 
reporting AA in pregnant women with pre-existing T1D or T2D during pregnancy 
(Berberovic et al., 2013 and Min et al., 2005). The first study (Berberovic et al., 2013) 
reported no statisticaly significant diferences between AA concentration and relative 
percentage in plasma total lipids of pregnant women with T1D compared to pregnant 
women without diabetes. The second study (Min et al., 2005) showed no significant 
differences in AA relative percentage between the diabetic (T1D and T2D) and non-
diabetic groups in multiple maternal blood pools (plasma TG, plasma choline 
phosphoglycerides, and RBC choline and ethanolamine phosphoglycerides). Although our 
finding of significantly higher AA relative percentage in maternal plasma total lipid of 
diabetic mothers is not exactly in line with the other two studies, this result is not 
surprising. In fact, the inconsistency in maternal AA relative percentage across these three 
studies could potentialy be the result of diferences in the participants’ diets prior to when 
the samples were colected. 
 
Umbilical cord DHA and AA levels  
 In the curent study we reported DHA and AA levels in the total lipids of umbilical 
cord serum and whole blood. In the umbilical cord serum total lipids, both DHA relative 
percentage and concentration were not statisticaly different between the diabetic and 
control groups. However, despite not being statisticaly significant, it is interesting to note 
that DHA concentration was approximately 19% lower in the diabetic umbilical cord 
serum total lipids compared to the control group. Similarly, umbilical cord whole blood 
total lipid DHA relative percentage and concentration were not significantly different 
between the diabetic and control groups. As for AA, umbilical cord serum total lipid AA 
concentration was approximately 16% lower in the diabetic group compared to the control 
group. However, the umbilical cord serum total lipid relative percentage of AA did not 
 44 
differ significantly between the diabetic and control groups. On the other hand, both AA 
relative percentage and concentration in the umbilical cord whole blood total lipids did not 
seem to differ significantly between the diabetic and the control group. In contrast to 
serum, whole blood samples contain plasma, RBCs, white blood cels, and platelets. 
Therefore, the faty acid composition from whole blood samples can be influenced by 
hematocrit, changes in white blood cel levels in response to infections, as wel as recent 
dietary intake of faty acids (Brenna et al., 2018). Since whole blood contains RBCs which 
are mainly composed of phospholipids, whole blood total lipid samples are composed of a 
relatively larger proportion of phospholipids compared to serum total lipids. When 
comparing DHA and AA levels between the umbilical cord serum and whole blood total 
lipids, it appears that both DHA and AA relative percentages and concentrations are higher 
in whole blood compared to serum total lipids for both the diabetic and the control groups. 
This indicates that DHA and AA are more concentrated in the phospholipids of the RBC 
membranes compared to the TGs and cholesteryl esters. Also, when comparing DHA and 
AA levels between the cord blood samples and the maternal plasma samples, it is evident 
that both DHA and AA relative percentage is higher in the umbilical cord serum and whole 
blood compared to the maternal plasma. Since DHA and AA accumulate in RBC 
membrane phospholipids, it makes sense that there would be relatively lower levels of 
DHA and AA compared to other faty acids in the TG- and cholesteryl esters-rich maternal 
plasma. Despite the maternal plasma having lower relative percentages of DHA and AA, 
its DHA and AA concentrations are relatively comparable to the umbilical cord samples. 
This discrepancy is the result of the maternal plasma samples having a higher concentration 
of total faty acids compared to the umbilical cord serum. 
 To this writer’s knowledge, there are four other studies that reported DHA levels 
(Ghebremeskel et al., 2004, Berberovic et al., 2013, Min et al., 2005, and Min et al., 2014) 
and three studies (Ghebremeskel et al., 2004, Berberovic et al., 2013, Min et al., 2005) that 
reported AA levels in the umbilical cord blood of pregnant women with pre-existing 
diabetes. Beginning with the studies that reported DHA results, the first study 
(Ghebremeskel et al., 2004) compared faty acid levels in the umbilical cord plasma 
choline phosphoglycerides, plasma TG, and plasma cholesterol esters in pregnant women 
with T1D (N = 31) and without diabetes (N = 59). The authors found the relative 
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percentage of DHA was approximately 27% and 42% lower in the umbilical cord plasma 
choline phosphoglycerides and cholesterol esters, respectively, of T1D mothers compared 
to non-diabetic mothers (Ghebremeskel et al., 2004). They also reported no significant 
difference in DHA relative percentage in the umbilical cord plasma TGs of the diabetic 
group compared to the non-diabetic group (Ghebremeskel et al., 2004). The Min et al., 
2005 also reported significantly lower DHA relative percentage in the umbilical cord 
plasma choline phosphoglycerides in T1D mothers but not in T2D mothers compared to the 
non-diabetic group. However, a later study also by Min and coleagues found significantly 
lower relative percentage of DHA in the umbilical cord plasma of T2D mothers compared 
to non-diabetic mothers (Min et al., 2014). Similarly, the Min et al., 2005 study also found 
significantly lower DHA relative percentage in the umbilical cord plasma TG in T1D 
mothers but not in T2D mothers compared to the non-diabetic group. Relative percentage 
of DHA also tended to be lower in the umbilical cord RBC choline and ethanolamine 
phosphoglycerides in diabetic mothers compared to non-diabetic mothers (Min et al., 2005 
and Min et al., 2014). Given these results, one could anticipate that relative percentage of 
DHA would also be lower in our study, but this was not the case. Instead, we found no 
significant difference in relative percentage of DHA in both umbilical cord serum and 
whole blood total lipids in the diabetic group compared to the non-diabetic group. The 
discrepancy between these results could be due to the differences in blood pools used in the 
studies. Like the maternal blood results discussed in the previous section, most of the 
differences in DHA levels observed in these studies were in the phospholipid pools 
whereas results in the TG pool are more mixed. Since our umbilical cord serum and whole 
blood samples contain the total lipids, it would be difficult to detect changes DHA levels 
that may be mainly present in the phospholipid class since the total lipid samples contain a 
greater proportion of TGs. Although the whole blood samples may contain more 
phospholipids compared to the serum samples, it stil contains a large proportion of TGs as 
it stil has the plasma component of the blood as wel. Therefore, it is possible that any 
differences in DHA in the phospholipids of our samples may be masked by the other lipid 
classes, namely the TGs. Similar to the curent study, the Berberovic et al., 2013 study also 
reported no significant diference in the relative percentage of DHA in the umbilical cord 
serum total lipids of T1D mothers compared to non-diabetic mothers. However, in contrast 
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to the curent study, Berberovic and coleagues reported significantly higher concentration 
of DHA in the umbilical cord serum total lipids of T1D mothers compared to non-diabetic 
mothers (Berberovic et al., 2013). It is unclear as to why Berberovic and coleagues found 
increased DHA concentration in diabetic cord blood when DHA has generaly been 
thought to be lower in diabetic cord blood compared to control (Léveilé et al., 2018). 
However, it is difficult to draw any conclusions about DHA concentration in diabetic cord 
blood as most studies in this area of research seem to report results in relative percentage 
rather than concentration. Taken altogether, the DHA results of the current study do not 
confirm the hypothesis of lower levels of DHA in the diabetic cord blood compared to the 
non-diabetic group nor are they exactly in line with the existing literature. In addition to the 
possibility of any differences in DHA levels being masked by pooling al the lipid classes 
together, the smal sample size of our study may also play a role in the lack of diference in 
DHA levels. The number of diabetic participants in our study (N = 7) is comparatively 
smaler than the other previous mentioned studies (N = 30-32) (Ghebremeskel et al., 2004, 
Berberovic et al., 2013, Min et al., 2005, and Min et al., 2014). It’s possible that our 
sample size is not large enough and therefore there is not enough statistical power to detect 
statisticaly significant differences in DHA levels in our umbilical cord blood samples. 
 Three of the four studies discussed in the previous paragraph also reported findings 
of AA levels in the umbilical cord blood of pregnant women with pre-existing diabetes 
compared those without diabetes (Ghebremeskel et al., 2004, Berberovic et al., 2013, and 
Min et al., 2005). Generaly, the studies reported a lower relative percentage of AA in the 
umbilical cord plasma choline phosphoglycerides, plasma cholesterol esters, and RBC 
choline phosphoglycerides of pregnant women with pre-existing diabetes compared to non-
diabetic compared to those without diabetes (Ghebremeskel et al., 2004 and Min et al., 
2005). These same two studies also found no statisticaly significant difference in AA 
relative percentage in the umbilical cord plasma TG of diabetic mothers compared to non-
diabetic mothers (Ghebremeskel et al., 2004 and Min et al., 2005). These results suggest 
that differences in AA levels occur mainly in the phospholipid class rather than the TG, 
meaning that these diferences could be masked if total lipid pools are used. In the case of 
the current study, we did not find any significant difference in umbilical cord serum total 
lipid AA relative percentage and whole blood total lipids AA relative percentage and 
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concentration in the diabetic versus the non-diabetic group. However, we did find 
significantly lower AA concentration in the umbilical cord serum total lipids of the diabetic 
group compared to the non-diabetic group. Again, our results difer from the Berberovic et 
al., 2013 study which found a significantly higher AA concentration and a non-significant 
difference in AA relative percentage in the umbilical vein serum total lipids of pregnant 
women with T1D compared to those without diabetes (Berberovic et al., 2013). The 
increase in AA concentration in the Berberovic study seems to be related to an increase in 
the overal concentration of faty acids in the T1D cord serum compared to the non-diabetic 
group (Berberovic et al., 2013). In contrast, we did not observe any significant diference 
in the total faty acid concentration in the umbilical cord serum total lipids between the 
diabetic and control groups. 
In the curent study, the significantly lower AA concentration in the umbilical cord 
serum total lipids of the diabetic group exists despite there being no diference in AA 
concentration and significantly higher AA relative percentage in the maternal plasma total 
lipids of the diabetic group compared to the control group. This disconnect between 
maternal and umbilical cord levels of AA is in line with the idea that there is a disturbance 
in the transfer of AA from mother to fetus in diabetic pregnancies and this could be related 
to the placenta storing DHA and AA. 
 
Placenta DHA and AA levels 
 In the curent study, we investigated the placenta faty acid profile and found no 
significant differences in DHA and AA relative percentage and concentration in the total 
lipids of both the maternal and fetal placenta between the diabetic and the non-diabetic 
groups. There are very few studies that report findings for placental levels of DHA and AA 
in diabetic pregnancies. To this writer’s knowledge, there is one study reporting placental 
AA levels in T1D pregnancies (Kuhn et al., 1990) and four reporting placental DHA and 
AA levels in GDM pregnancies (Bitsanis et al., 2006, Prieto-Sánchez et al., 2017, Segura 
et al., 2017, and Uhl et al., 2015). Kuhn and coleagues found that a greater percentage of 
AA is incorporated into the placenta TGs in T1D mothers compared to non-diabetic 
mothers (Kuhn et al., 1990). They also showed that a smaler percent of AA incorporated 
into the placenta phosphoglycerides and free faty acid fractions in T1D pregnancies 
 48 
compared to non-diabetics (Kuhn et al., 1990). In the case of GDM, it seems that the 
relative percentage of DHA and AA is higher in the placenta phospholipids in GDM 
compared to non-diabetic pregnancies (Bitsanis et al., 2006 and Uhl et al., 2015). 
However, one study reported no diference in DHA and AA relative percentage in placenta 
phospholipids in GDM compared to non-diabetic pregnancies (Segura et al., 2017). In 
addition, one study found no diference in DHA and a lower AA relative percentage in 
placenta TG of GDM compared to non-diabetic women (Bitsanis et al., 2006) whereas 
another study found no significant difference in DHA and AA levels in placenta TGs of 
GDM versus non-diabetic women (Segura et al., 2017). Another study also reported no 
significant difference in DHA and AA relative percentage in placenta total lipids of GDM 
compared to non-diabetic participants (Prieto-Sánchez et al., 2017). To this writer’s 
knowledge, there are no studies reporting placental DHA and AA levels in T2D women. 
Although placenta DHA and AA levels did not seem to differ between the diabetic and the 
non-diabetic group in the current study, it could be the case that measuring these faty acids 
in the placenta total lipids may mask any diferences that are occurring in the individual 
lipid classes. Since it appears that most of the previously mentioned studies found 
differences in DHA and AA levels in placenta phospholipids, it would be interesting to 
determine the faty acid composition of the placenta phospholipids in the maternal and fetal 
placenta samples from the curent study. 
 The placenta results from the current study indicate that there is no significant 
accumulation of neither DHA nor AA in the maternal and fetal placenta in the diabetic 
group compared to the non-diabetic group. The concept of DHA and AA accumulating in 
the placenta is one possible hypothesis for the mechanism behind the lower transfer of 
these faty acids from mother to fetus in diabetic pregnancies, but our current results do not 
support this concept.  
Another hypothesis for the reduced transfer of faty acids from mother to fetus in 
diabetic pregnancies is related to the impaired uptake and transportation of these faty acids 
across the placenta. One study reported disturbed placental uptake of 13C-DHA in GDM 
compared to non-diabetic placentas (Larqué et al., 2014). In addition, placental uptake of 
13C-DHA is lower in obese pregnant women compared to non-obese pregnant women 
(Gázquez et al., 2019). This has implications for T1D and T2D pregnant women since 
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obesity is common in individuals with diabetes (Punthakee et al., 2018). In theory, the 
disturbance in placental uptake of faty acids such as DHA and AA could be the result of 
differences in the expression of placental faty acid transporters in diabetic pregnancies, 
therefore interfering with the transfer of faty acids from mother to fetus. As previously 
discussed, there is some evidence for changes in the expression of placental faty acid 
transporters in T1D and GDM pregnancies (Magnusson et al., 2004, Radaeli et al., 2009, 
Prieto-Sánchez et al., 2017, and Segura et al., 2017). However, only one of these studies 
reports findings in pre-existing T1D during pregnancy (Radaeli et al., 2009). Further, there 
are no studies reporting the expression of placental faty acid transporters in T2D. 
Therefore, it is dificult to draw any firm conclusions about the level of expression of faty 
acid transporters in the placentas of women with pre-existing T1D and T2D during 
pregnancy. 
In summary, we found a lower transfer of AA from mother to fetus in diabetic 
pregnancies. However, the placental faty acid profile results of the current study do not 
support the hypothesis of the accumulation of AA and DHA in the placenta of T1D and 
T2D women compared to non-diabetic women. Given the importance of AA for 
neurodevelopment, we wanted to assess if this lower transfer from mother to fetus during 
gestation impacted the neurodevelopment of the neonates from the diabetic group.  
 
Neurodevelopment (EEG) 
 The first measure of neurodevelopment used in the current study is coherence, 
which is the correlation between oscilations of activity from the same brain region 
between the two hemispheres. Most of the statisticaly significant diferences observed 
were differences between the two time points within the same group. In other words, we 
mainly observed slight increases in coherence between the first EEG (24 – 48 hours after 
birth) and the second EEG (at 48 weeks post-amenorrhea) and not between newborns from 
control vs pre-existing diabetes mothers. The neonates, particularly those from the control 
group, exhibited increases in coherence in the theta, alpha, and beta frequency bands of the 
frontal regions. This is thought to be associated with post-natal maturation and with the 
development of thalamocortical connections of higher and more complex frequencies 
(Meijer et al., 2014). Coherence in the fronto-temporal region differed slightly between the 
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neonates from diabetic mothers and the neonates from non-diabetic mothers at the first 
EEG. However, these are diferences of 0.01 – 0.03. Since coherence is a correlation 
coefficient, it is evident that a difference in correlation of 0.01 – 0.03, while statisticaly 
significant, may not necessarily be clinicaly relevant. The pilot EEG study that was 
previously performed in our laboratory on neonates from GDM mothers also found no 
significant difference in coherence between the neonates from GDM mothers compared to 
neonates from non-diabetic mothers at ≤ 48 hours after birth (Léveilé et al., 2018). 
 The second measure of neurodevelopment used was PSD, which is the distribution 
of the signal power over frequency of the signal from each electrode. In line with the 
coherence results, the statisticaly significant differences in PSD were within the same 
group between the first and second EEGs. Neonates from both the diabetic and non-
diabetic group exhibited increases in PSD between the first EEG and the second EEG in 
the delta and theta frequency bands of the right and left temporo-occipital and the right and 
left centro-occipital electrodes. However, these increases in PSD between the first and 
second EEG were not statisticaly significant in the diabetic group. These increases in PSD 
observed in the delta and theta frequency bands of the occipital regions between the first 
and second EEG may be related to the establishment of the posterior dominant rhythm, a 
rhythm established around 2 months of age and typicaly in the 3 – 4 Hz frequency (Briton 
et al., 2016). This is a normal part of neurodevelopment and precedes the alpha rhythm, 
which is the dominant rhythm of activity in the adult brain (Briton et al., 2016). We did 
not observe any diferences in PSD between the neonates from the diabetic and the control 
groups at either the first EEG or the second EEG. In contrast, Léveilé and coleagues 
observed lower PSD in the left centro-occipital region in neonates from GDM mothers 
compared to neonates from non-diabetic mothers at ≤ 48 hours after birth (Léveilé et al., 
2018). However, these results were no longer statisticaly significant after adjustment for 
gestational age (Léveilé et al., 2018). This indicates that the diference in PSD in the 
centro-occipital region was likely due to diferences in gestational age rather than GDM. 
The diference in gestational age between the diabetic and the control group is similar in 
the current study compared to the Léveilé et al., 2018 study. However, unlike Léveilé and 
coleagues, the current study does not report data on neonatal hypoglycemia, a condition 
which is common in offspring of diabetic mothers and can negatively impact 
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neurodevelopment (Boluyt et al., 2006). The current study also demonstrated higher 
coherence and PSD in the low-frequency range, particularly the delta frequency band (< 4 
Hz), compared to other frequency ranges for al brain regions. This makes sense since the 
low-frequency range is the dominant infants ≤ 1 year of age since they spend a large 
proportion of their time sleeping. This same patern was also observed in the neonates from 
the Léveilé et al., 2018 study and in infants at 0 - 3 months and 4 – 6 months of age 
(Cornelissen et al., 2015). 
 Overal, the changes in coherence and PSD between the first and second EEG 
observed in the neonates of the current study indicate normal neurodevelopment between 
birth and approximately two months of age. Moreover, we did not observe any 
abnormalities in the EEG coherence and PSD in the neonates from the diabetic group 
compared to the neonates from the control group. Therefore, we did not find any evidence 
of impaired neurodevelopment in the infants of diabetic mothers.  
Our study is the first to evaluate neurodevelopment using EEG at birth in neonates 
of T1D and T2D mothers compared to non-diabetic mothers. As previously described in 
the introduction, most of the studies that investigate cognitive scores in ofspring of 
diabetic mothers evaluate the children later in life (Brincioti et al., 2009, de Regnier et al., 
2000, Silverman et al., 1998, Fraser et al., 2012, Clausen et al., 2013, Temple et al., 2011, 
Bytoft et al., 2016, Clausen et al., 2011, Xiang et al., 2018, and Bytoft et al., 2017). It is 
therefore not clear whether DHA and AA transfer is at the root of the lower cognitive 
scores observed in offspring of diabetic mothers or if there are other environmental factors 
that influence these scores. In the curent study, we determined that there was a lower 
transfer of AA but not DHA from mother to fetus in the diabetic group and that the 
neonates from the diabetic did not appear to have abnormalities in their coherence and PSD 
compared to neonates from non-diabetic mothers. This absence of evidence for impaired 
neurodevelopment in the neonates from the diabetic group occured despite evidence for 
lower AA transfer from mother to fetus. As previously discussed, AA concentration was 
approximately 16% lower in the umbilical cord serum total lipids of the diabetic group 
compared to the control group. In addition, the concentration of DHA in the umbilical cord 
serum total lipids was approximately 19% lower in the diabetic group compared to the non-
diabetic group, although this was not statisticaly significant. Given the importance of these 
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two faty acids for fetal brain development (Sastry 1985 and Innis 2007), it would be 
logical to assume that a deficiency in those faty acids would be detrimental for the fetus’s 
neurodevelopment. One study found a positive corelation between neurological optimality 
score and umbilical vein and artery DHA and umbilical vein AA in 317 infants 10-14 days 
after birth (Dijck-Brouwer et al., 2005). Another study reported that 3-month-old infants 
with mildly abnormal general movements had a lower relative percentage of AA in their 
umbilical artery compared to infants with normal general movements (Bouwstra et al., 
2006). Moreover, another study stated that 18-month-old children with minor neurological 
function had lower umbilical vein DHA compared to neurotypical children (van Goor et 
al., 2011). The authors also identified weak positive association between umbilical vein 
AA and the Bayley Scales of Infant Development mental development index (van Goor et 
al., 2011). It was estimated that the human fetus accumulates 41.65 mg DHA/day and 
95.25 mg AA/day during weeks 35-40 of gestation (Kuipers et al., 2012). It is possible that 
perhaps the infants from diabetic mothers in the current study had a lower transfer of AA 
compared to the control group, but the amount of AA and DHA transfered was stil 
sufficient to meet the needs of their brain development in utero.  
  
Strengths and limitations 
Strengths 
One strength of the current study is that the faty acid results were reported in both 
relative percentage and concentration. This is unique compared to other studies in the field 
which usualy communicate faty acid results in relative percentage only. While the relative 
percentage of a faty acid is useful knowledge, it does not give the ful picture. For 
instance, the relative percentage of AA in the umbilical cord serum total lipids did not 
differ significantly between the diabetic and non-diabetic group. However, the umbilical 
cord serum AA concentration was significantly lower in the diabetic group compared to the 
non-diabetic group. When only considering the relative percentage of AA in this case, it 
would seem like there is no difference when that is clearly not the case. Another problem 
with only reporting relative percentage is that not al studies include the same list of faty 
acids (Brenna et al., 2018). For instance, some authors might include 10 faty acids while 
others might include 15. This could drasticaly impact the resulting relative percentages, 
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thus making it difficult to compare relative percentages between studies. In contrast, faty 
acid concentrations are more reflective of the available faty acids and can be more easily 
compared between studies (Brenna et al., 2018). 
 The current study is also the first study in this area of research to report the faty 
acid profile of a wide variety of samples. While it may be more common to report findings 
in the maternal and umbilical cord blood pools, very few studies also include the faty acid 
composition of the placenta. In fact, to this writer’s knowledge, this is the first study 
examining the faty acid profile of the maternal and fetal placentas in T1D and T2D 
pregnancies. 
 In addition, the current study is one of the first studies to evaluate both umbilical 
cord levels of DHA and AA and neurodevelopment at birth in infants from T1D and T2D 
mothers. This type of study can provide more insight on the direct link between DHA and 
AA transfer from mother to fetus and whether this has an impact on the neonate’s brain 
development. We know based on previous studies that pregnancies complicated by pre-
existing T1D and T2D are associated with negative cognitive outcomes for the offspring 
long-term (Brincioti et al., 2009, de Regnier et al., 2000, Silverman et al., 1998, Fraser et 
al., 2012, Clausen et al., 2013, Temple et al., 2011, Bytoft et al., 2016, Clausen et al., 
2011, Xiang et al., 2018, and Bytoft et al., 2017). This type of study alows us to 
investigate whether these cognitive deficits are present soon after birth and whether they 
might be related to decreased DHA and AA transfer from mother to fetus. 
 The final strength of the current study is the use of EEGs at two time points. Since 
diabetic pregnancies are associated with increased risk of fetal macrosomia, it is common 
to induce labour so that the infant is born before ful term (Mozurkewich et al., 2008). This 
could result in differences in gestational age between groups. For instance, in the current 
study, neonates from the diabetic group were an average gestational age of 38.1 ± 0.9 
weeks compared to 40.0 ± 1.1 weeks in the control group. During this period of rapid brain 
growth and development, two weeks of gestational age can make a difference when 
assessing neurodevelopment. For example, Léveilé and coleagues observed lower PSD in 
left centro-occipital region the infants from the diabetic group compared to the non-
diabetic group, but this difference was no longer significant after adjustment for gestational 
age. The second EEG in our current study serves as a method of adjusting for gestational 
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age. The second EEG was performed 48 weeks post-amenorrhea (which equates to 
approximately two months of age). Since the timing of the second EEG is based on 
amenorrhea and not the birth date, it does not mater if one group of infants was born on 
average two weeks earlier than the other group. Therefore, the second EEG was performed 
in infants of equivalent age despite their differing gestational age at birth. In addition, 
having two EEGs alows us to compare neurodevelopment between birth and 2 months of 
age and to determine whether brain maturation occurred as expected. 
 
Limitations 
The main limitation of the current study is the smal sample size, particularly of the 
diabetic group. Throughout recruitment during the years 2017 – 2020, we were only able to 
successfuly recruit 7 diabetic participants. Only a smal percentage of pregnant women 
have pre-existing T1D and T2D; Feig et al. observed that 1.5% of pregnancies in Ontario, 
Canada in 2010 were complicated by pre-existing T1D and T2D (Feig et al., 2014). This in 
combination with the exclusion criteria and the dificulty of colecting samples during 
unpredictable labour and delivery times contributed to our smal sample size. Of the 
diabetic participants that were recruited, not al of them completed the EEGs. This resulted 
in the even smaler sample size of N = 4 for the first EEG and N = 3 for the second EEG. 
This smaler sample size of the diabetic group can impact the power of the study and 
therefore make it more dificult to detect statisticaly significant differences, particularly in 
the case of smal effect sizes such as in comparison of DHA levels. Furthermore, the 
diabetic group was composed of five T2D mothers and two T1D. The rationale for 
grouping both T1D and T2D mothers together was because T1D and T2D during 
pregnancy is associated with more hyperglycemic and hypoglycemic episodes compared to 
GDM pregnancies. Moreover, the hyperglycemia is present from the beginning of gestation 
in T1D and T2D compared to GDM which develops over the course of the pregnancy. 
However, it would have been desired to have enough participants of both T1D and T2D so 
that they may be considered separately as wel. This would have been particularly useful 
when comparing the DHA and AA findings with the previous studies, namely the 
Berberovic et al., 2013 study which seemed to have conflicting findings compared to the 
other studies reporting maternal and umbilical cord DHA and AA levels in diabetic 
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pregnancies (Ghebremeskel et al., 2004, Min et al., 2005, and Min et al., 2014). However, 
despite the smal sample size of the diabetic group, we were stil able to detect some 
significant differences in the faty acid composition of the maternal plasma and umbilical 
cord serum total lipids. The fact that we were able to find differences in faty acid 
composition despite the smal sample size potentialy speaks to the strength of the effect. 
The faty acid findings were also in line with some of the previous studies, which further 
confirms the validity of the findings of the curent research project. 
Another potential limitation of our study is the use of passive EEG instead of an 
evoked potential EEG. By measuring the brain activity of the infants using passive EEG, 
we were able to observe their general brain activity at rest. The advantage of this is that it 
was a practice that had already been previously implemented by our laboratory and 
colaborators in a previous study (Léveilé et al., 2018) which then alowed us to compare 
these results directly with the previous pilot EEG study. On the other hand, using evoked 
potential can alow researchers to target more specific types of brain activity to assess 
specific functions such as the functioning of the visual system, the functioning of the 
auditory system, recognition memory, etc. Using evoked potentials could have also been 
useful in comparing our results to the previous studies that had assessed evoked potentials 
in infants of diabetic mothers (Brincioti et al., 2009 and de Regnier et al., 2000). 
Another limitation of the curent study is the use of multiple comparisons. When 
performing multiple statistical tests such as t-tests, there is a chance that some of the 
findings are a false positive. The writer of this document chose to focus the discussion on 
the primary outcome to limit multiple comparisons. In addition, given the two time-point 
design of the EEG portion of our study, it would have been ideal to use a two-way repeated 
measure analysis in order to compare groups. However, because of an error in the handling 
of the EEG data files, we were not able to identify and match up specific individuals 
beyond just the group in which they belonged. As a result, we are unable to pair the two 
time points from the same individual. Because of this constraint, we compared means 
between groups and time points using the Mann Whitney test. 
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Future directions 
The current study reported faty acid composition in the total lipids of various 
sample types. As previously discussed, many of the existing studies that investigated DHA 
and AA levels in maternal blood and umbilical cord blood in diabetic pregnancies reported 
findings in specific lipid classes such as phospholipids and TGs (Ghebremeskel et al., 
2004, Berberovic et al., 2013, Min et al., 2005, Min et al., 2014, Bitsanis et al., 2006, 
Prieto-Sánchez et al., 2017, Segura et al., 2017, Uhl et al., 2015, and Kuhn et al., 1990). 
Moreover, DHA and AA are highly concentrated in phospholipids and many of the 
aforementioned studies reported differences in DHA and AA levels in the phospholipid 
class. However, differences in the faty acid composition of the phospholipid fraction can 
be masked by other lipids such as TGs when analyzing the faty acid composition of total 
lipids (Brenna et al., 2018). Given this, it would be useful to analyze the faty acid 
composition of TGs, phospholipids, free faty acids, cholesterol esters in the maternal 
plasma, umbilical cord serum, umbilical cord whole blood, and maternal and fetal placenta. 
This would alow for more direct comparisons with findings in the curent literature. In 
addition, it would reveal whether DHA levels differ in specific lipid classes such as the 
phospholipids in the umbilical cord serum of the diabetic group compared to the non-
diabetic group.  
 Another potential avenue of research for this project would be to evaluate the level 
of expression of faty acid transporters in the maternal and fetal placenta. As previously 
discussed, some studies have found evidence of changes in placental faty acid transporter 
expression in GDM and T1D pregnancies (Magnusson et al., 2004, Radaeli et al., 2009, 
Prieto-Sánchez et al., 2017, and Segura et al., 2017). However, to this writer’s knowledge, 
there are no studies in the literature that report the level of expression of placental faty acid 
transporters in T2D pregnancies. Performing these analyses in our cohort would result in 
the first report of faty acid transporter expression in the placenta of T2D women. This 
would shed light on a potential mechanism for the lower transfer of faty acids from mother 
to fetus in T1D and T2D diabetic pregnancies. We had already begun to analyze placental 
faty acid transporters (specificaly MFSD2A, FABP4, FATP4, and CD36) by Western 
Blot, but we had encountered many hurdles in the process. Firstly, it was dificult to find 
antibodies that were reliable and specific to the proteins that we were investigating. Given 
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this, we began the process of developing pure proteins to use as a positive control in our 
Western Blot experiments. This process was halted earlier this year because of the 
coronavirus disease of 2019 (COVID-19). Because of delays associated with laboratories 
being closed down from the pandemic, we were unable to produce results for the placental 
faty acid transporter levels. 
 
Conclusion 
 The current study demonstrated that there is a significantly lower concentration of 
AA in the umbilical cord serum total lipids in T1D and T2D women compared to non-
diabetic women. On the other hand, the concentration of DHA in the umbilical cord serum 
total lipids in T1D and T2D women compared to non-diabetic women did not differ 
significantly. These lower levels of umbilical cord AA are present despite similar levels of 
these faty acids in the maternal plasma of both the diabetic and control groups. This 
indicates that there is a dysfunction at the level of the placenta that results in a decreased 
transfer of AA from mother to fetus in diabetic pregnancies. The current study does not 
provide evidence of accumulation of AA or DHA in the placenta of diabetic mothers, so 
this dysfunction may be at the level of the placental faty acid transporters. Despite this 
lower level of cord blood serum AA, we were unable to find evidence of impaired 
neurodevelopment in the EEGs of infants of diabetic mothers 24-48 hours after birth and 
again at 48 weeks post-amenorrhea. This implies that these infants have similar 
neurodevelopment to their counterparts in the control group. 
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6APPENDICES 
Appendix 1 Maternal plasma faty acid relative percentage and concentration in total lipids 
from control and diabetic mothers. 
 Relative Percentage (%) Concentration (mg/dL) 
Faty acid 
Controls 
(n = 24) 
Diabetics 
(n = 7) 
P value 
Controls 
(n = 24) 
Diabetics 
(n = 7) 
P value 
C14:0 1.01 ± 0.08 0.58 ± 0.07 0.009 4.9 ± 0.5 2.5 ± 0.4 0.010 
C16:0 27.20 ± 0.44 25.89 ± 0.60 0.148 131.1 ± 6.2 112.0 ± 8.9 0.136 
C16:1n-7 trans 0.40 ± 0.02 0.35 ± 0.03 0.161 1.9 ± 0.1 1.5 ± 0.2 0.125 
C16:1n-7 2.31 ± 0.17 1.54 ± 0.17 0.028 11.2 ± 0.9 6.5 ± 0.7 <0.001 
C18:0 5.29 ± 0.10 5.546 ± 0.34 0.498 25.1 ± 0.8 23.7 ± 1.9 0.445 
C18:1n-9 24.17 ± 0.44 25.37 ± 0.93 0.220 116.1 ± 5.4 111.8 ± 12.0 0.716 
C18:1n-7 1.79 ± 0.06 1.88 ± 0.06 0.404 8.6 ± 0.5 8.2 ± 0.8 0.689 
C18:2n-6 28.47 ± 0.64 28.24 ± 1.03 0.856 135.3 ± 5.1 121.7 ± 9.7 0.417 
C18:3n-3 0.90 ± 0.04 0.84 ± 0.07 0.543 4.4 ± 0.3 3.6 ± 0.2 0.370 
C20:3n-6 1.63 ± 0.07 1.75 ± 0.16 0.652 7.7 ± 0.4 7.6 ± 1.0 0.911 
C20:4n-6 5.06 ± 0.19 6.04 ± 0.61 0.049 24.1 ± 1.3 26.0 ± 3.3 0.526 
C20:5n-3 0.29 ± 0.03  0.35 ± 0.08 0.539 1.4 ± 0.1 1.4 ± 0.2 0.695 
C22:5n-3 0.21 ± 0.01 0.22 ± 0.02 0.769 1.0 ± 0.1 0.9 ± 0.1 0.632 
C22:6n-3 1.30 ± 0.08  1.41 ± 0.09 0.473 6.1 ± 0.4 6.1 ± 0.6 0.932 
       
Saturated 33.50 ± 0.48 32.03 ± 0.71 0.136 161.1 ± 7.2 138.3 ± 10.4 0.126 
Monounsaturated 28.65 ± 0.44 29.13 ± 0.97 0.624 137.8 ± 6.3 128.0 ± 13.4 0.480 
N-3 PUFA 2.69 ± 0.11 2.82 ± 0.18 0.581 12.9 ± 0.7 11.9 ± 0.7 0.509 
N-6 PUFA 35.16 ± 0.60 36.03 ± 1.16 0.503 167.2 ± 6.0 155.4 ± 12.1 0.835 
PUFA 37.85 ± 0.61 38.84 ± 1.24 0.452 180.0 ± 6.5 167.3 ± 12.6 0.695 
Total 100 100  479.0 ± 18.8 433.6 ± 34.7 0.260 
Abbreviations: N-3 PUFA, omega-3 polyunsaturated faty acids; N-6, omega-6 polyunsaturated faty acids; 
PUFA, polyunsaturated faty acids; Statistical diferences between group means were determined using either 
independent t-tests or Mann Whitney tests, as appropriate. Statistical significance is denoted by P value in 
bold. Data is presented as mean ± standard eror of the mean. 
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Appendix 2 Umbilical cord serum faty acid relative percentage and concentration in total 
lipids from control and diabetic mothers. 
 Relative Percentage (%) Concentration (mg/dL) 
Faty acid 
Controls 
(n = 24) 
Diabetics 
(n = 7) 
P value 
Controls 
(n = 24) 
Diabetics 
(n = 7) 
P value 
C14:0 0.65 ± 0.05 0.74 ± 0.26 0.555 0.7 ± 0.1 0.7 ± 0.3 0.465 
C16:0 26.04 ± 0.36 24.97 ± 0.78 0.182 28.1 ± 1.2 24.4 ± 2.0 0.115 
C16:1n-7 trans 0.70 ± 0.04 0.57 ± 0.08 0.026 0.8 ± 0.1 0.6 ± 0.1 0.007 
C16:1n-7 3.44 ± 0.13 3.58 ± 0.44 0.753 3.8 ± 0.2 3.6 ± 0.7 0.346 
C18:0 10.19 ± 0.15 10.55 ± 0.24 0.248 11.0 ± 0.4 10.3 ± 0.5 0.395 
C18:1n-9 19.74 ± 0.49 21.40 ± 0.73 0.108 21.7 ± 1.3 21.0 ± 1.8 0.945 
C18:1n-7 3.24 ± 0.09 3.96 ± 0.17 <0.001 3.5 ± 0.2 3.9 ± 0.4 0.336 
C18:2n-6 12.79 ± 0.47 11.34 ± 0.35 0.021 13.8 ± 0.8 11.0 ± 0.5 0.005 
C18:3n-3 0.78 ± 0.16 1.39 ± 0.57 0.636 0.9 ± 0.2 1.4 ± 0.6 0.738 
C20:3n-6 3.55 ± 0.11 3.70 ± 0.20 0.494 3.8 ± 0.2 3.6 ± 0.3 0.527 
C20:4n-6 14.23 ± 0.37 13.47 ± 0.90 0.368 15.3 ± 0.7 12.9 ± 0.7 0.019 
C20:5n-3 0.29 ± 0.02 0.31 ± 0.03 0.539 0.3 ± <0.1 0.3 ± <0.1 0.773 
C22:5n-3 0.39± 0.03 0.33 ± 0.06 0.355 0.4 ± <0.1 0.3 ± <0.1 0.190 
C22:6n-3 3.97 ± 0.19 3.69 ± 0.37 0.484 4.3 ± 0.3 3.5 ± 0.3 0.146 
       
Saturated 36.88 ± 0.37 36.27 ± 0.43 0.412 39.8 ± 1.7 35.4 ± 2.4 0.216 
Monounsaturated 27.12 ± 0.65 29.51 ± 1.34 0.097 29.7 ± 1.8 29.0 ± 2.9 0.800 
N-3 PUFA 5.42 ± 0.28 5.72 ± 0.77 0.661 5.9 ± 0.4 5.5 ± 0.8 0.636 
N-6 PUFA 30.58 ± 0.57 28.51 ± 1.11 0.100 32.9 ± 1.4 27.5 ± 1.1 0.019 
PUFA 36.00 ± 0.68 34.23 ± 1.68 0.259 38.9 ± 1.8 33.0 ± 1.6 0.061 
Total 100 100 0.555 108.4 ± 4.9 97.4 ± 5.8 0.317 
Abbreviations: N-3 PUFA, omega-3 polyunsaturated faty acids; N-6, omega-6 polyunsaturated faty acids; 
PUFA, polyunsaturated faty acids; Statistical diferences between group means were determined using either 
independent t-tests or Mann Whitney tests, as appropriate. Statistical significance is denoted by P value in 
bold. Data is presented as mean ± standard eror of the mean. 
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Appendix 3 Umbilical cord whole blood faty acid relative percentage and concentration in 
total lipids from control and diabetic mothers. 
 Relative Percentage (%) Concentration (mg/dL) 
Faty acid 
Controls 
(n = 24) 
Diabetics 
(n = 7) 
P value 
Controls 
(n = 24) 
Diabetics 
(n = 7) 
P value 
C14:0 0.45± 0.04 0.49 ± 0.11 0.991 0.8 ± 0.1 0.8 ± 0.2 0.755 
C16:0 27.14 ± 0.47 26.82 ± 0.48 0.732 42.4 ± 2.0 44.8 ± 3.5 0.563 
C16:1n-7 trans 0.60 ± 0.03 0.54 ± 0.08 0.149 1.0 ± 0.1 0.9 ± 0.2 0.742 
C16:1n-7 2.16 ± 0.12 2.00 ± 0.34 0.270 3.5 ± 0.3 3.4 ± 0.7 0.738 
C18:0 10.06 ± 0.80 11.06 ± 1.49 0.391 14.7 ± 0.6 18.0 ± 2.4 0.234 
C18:1n-9 14.52 ± 0.31 14.64 ± 0.52 0.852 22.8 ± 1.3 24.4 ± 1.9 0.554 
C18:1n-7 2.47 ± 0.06 2.72 ± 0.12 0.076 3.9 ± 0.2 4.5 ± 0.4 0.124 
C18:2n-6 9.43 ± 0.41 7.91 ± 0.37 0.062 15.1 ± 1.2 13.4 ± 1.3 0.460 
C18:3n-3 0.16 ± 0.02 0.11 ± 0.02 0.170 0.3 ± <0.1 0.2 ± <0.1 0.524 
C20:3n-6 3.66 ± 0.10 4.00 ± 0.26 0.204 5.7 ± 0.3 6.7 ± 0.7 0.203 
C20:4n-6 21.90 ± 0.58 22.36 ± 1.00 0.706 35.1 ± 2.4 37.6 ± 3.8 0.622 
C20:5n-3 0.30 ± 0.03 0.31 ± 0.03 0.437 0.5 ± 0.1 0.5 ± 0.1 0.555 
C22:5n-3 0.71 ± 0.04 0.85 ± 0.15 0.410 1.2 ± 0.1 1.4 ± 0.3 0.258 
C22:6n-3 6.47 ± 0.38 6.24 ± 0.44 0.763 10.6 ± 1.0 10.5 ± 1.2 0.729 
       
Saturated 37.65 ± 0.93 38.37 ± 1.45 0.707 57.9 ± 2.0 63.7 ± 4.8 0.207 
Monounsaturated 19.74 ± 0.41 19.88 ± 0.97 0.875 31.2 ± 1.8 33.2 ± 3.0 0.585 
N-3 PUFA 7.63 ± 0.44 7.52 ± 0.52 0.894 12.5 ± 1.2 12.7 ± 1.5 0.627 
N-6 PUFA 34.98 ± 0.74 34.23 ± 1.22 0.625 56.0 ± 3.7 57.6 ± 5.5 0.826 
PUFA 42.62 ± 1.00 41.75 ± 1.60 0.674 68.4 ± 4.8 70.3 ± 6.8 0.847 
Total 100 100  157.4 ± 8.2 167.2 ± 12.9 0.566 
Abbreviations: N-3 PUFA, omega-3 polyunsaturated faty acids; N-6, omega-6 polyunsaturated faty acids; 
PUFA, polyunsaturated faty acids; Statistical diferences between group means were determined using either 
independent t-tests or Mann Whitney tests, as appropriate. Statistical significance is denoted by P value in 
bold. Data is presented as mean ± standard eror of the mean. 
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Appendix 4 Maternal placenta faty acid relative percentage and concentration in total 
lipids from control and diabetic mothers. 
 Relative Percentage (%) Concentration (µg/g) 
Faty acid 
Controls 
(n = 25) 
Diabetics 
(n = 7) 
P value 
Controls 
(n = 25) 
Diabetics 
(n = 7) 
P value 
C14:0 0.25 ± 0.03 0.15 ± 0.05 0.144 28 ± 4 16 ± 7 0.228 
C16:0 24.37 ± 0.63 22.71 ± 0.80 0.201 2478 ± 194 2004 ± 336 0.255 
C16:1n-7 trans 0.28 ± 0.02 0.24 ± 0.03 0.295 30 ± 3 22 ± 6 0.296 
C16:1n-7 0.63 ± 0.04 0.45 ± 0.07 0.053 67 ± 8 42 ± 13 0.085 
C18:0 11.19 ± 0.78 13.18 ± 1.03 0.302 1014 ± 45 1079 ± 97 0.517 
C18:1n-9 10.74 ± 0.20 11.59 ± 0.47 0.044 1058 ± 60 989 ± 122 0.599 
C18:1n-7 1.70 ± 0.04 1.86 ± 0.07 0.044 167 ± 9 160 ± 24 0.733 
C18:2n-6 13.71 ± 0.48 12.21 ± 0.60 0.094 1399 ± 118 1089 ± 210 0.286 
C18:3n-3 0.18 ± 0.01 0.16 ± 0.01 0.503 19 ± 2 15 ± 3 0.440 
C20:3n-6 6.25 ± 0.19 6.21 ± 0.61 0.934 610 ± 34 531 ± 80 0.312 
C20:4n-6 25.40 ± 0.44 25.40 ± 0.48 0.999 2543 ± 180 2206 ± 331 0.386 
C20:5n-3 0.19 ± 0.02 0.19 ± 0.02 0.647 20 ± 2 16 ± 3 0.599 
C22:5n-3 0.86 ± 0.04 0.99 ± 0.04 0.077 83 ± 5 83 ± 9 0.985 
C22:6n-3 4.51 ± 0.17 4.82 ± 0.37 0.427 444 ± 32 400 ± 39 0.696 
       
Saturated 35.81 ± 0.45 36.05 ± 0.84 0.806 3520 ± 193 3097 ± 399 0.322 
Monounsaturated 13.35 ± 0.21 14.13 ± 0.52 0.221 1320 ± 79 1211 ± 163 0.533 
N-3 PUFA 5.73 ± 0.19 6.15 ± 0.40 0.329 566 ± 39 514 ± 52 0.517 
N-6 PUFA 45.36 ± 0.49 43.82 ± 1.10 0.168 4550 ± 318 3824 ± 610 0.295 
PUFA 51.09 ± 0.50 49.97 ± 0.86 0.291 5116 ± 349 4341 ± 651 0.306 
Total 100 0.15 ± 0.05 0.144 9957 ± 612 8654 ± 1193 0.330 
Abbreviations: N-3 PUFA, omega-3 polyunsaturated faty acids; N-6, omega-6 polyunsaturated faty acids; 
PUFA, polyunsaturated faty acids; Statistical diferences between group means were determined using either 
independent t-tests or Mann Whitney tests, as appropriate. Statistical significance is denoted by P value in 
bold. Data is presented as mean ± standard eror of the mean. 
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Appendix 5 Fetal placenta faty acid relative percentage and concentration in total lipids 
from control and diabetic mothers. 
 Relative Percentage (%) Concentration (µg/g) 
Faty acid 
Controls 
(n = 25) 
Diabetics 
(n = 7) 
P value 
Controls 
(n = 25) 
Diabetics 
(n = 7) 
P value 
C14:0 0.38 ± 0.03 0.31 ± 0.02 0.102 32 ± 3 24 ± 3 0.265 
C16:0 26.00 ± 0.42 25.89 ± 0.35 0.650 2119 ± 114 1960 ± 144 0.493 
C16:1n-7 trans 0.34 ± 0.02 0.31 ± 0.03 0.467 28 ± 2 24 ± 3 0.318 
C16:1n-7 0.74 ± 0.04 0.57 ± 0.05 0.063 60 ± 5 44 ± 5 0.083 
C18:0 13.03 ± 0.56 14.20 ± 0.21 0.416 1030 ± 53 1074 ± 74 0.687 
C18:1n-9 11.79 ± 0.27 11.82 ± 0.36 0.955 939 ± 33 889 ± 63 0.476 
C18:1n-7 1.72 ± 0.04 1.79 ± 0.09 0.386 138 ± 6 134 ± 14 0.761 
C18:2n-6 13.45 ± 0.45 11.91 ± 0.26 0.062 1087 ± 66 903 ± 70 0.144 
C18:3n-3 0.19 ± 0.01 0.16 ± 0.02 0.385 15 ± 1 12 ± 1 0.350 
C20:3n-6 5.45 ± 0.15 5.58 ± 0.51 0.818 440 ± 24 423 ± 55 0.467 
C20:4n-6 22.28 ± 0.35 22.69 ± 0.28 0.370 1808 ± 91 1713 ± 116 0.607 
C20:5n-3 0.18 ± 0.01 0.19 ± 0.03 0.763 14 ± 1 14 ± 2 0.902 
C22:5n-3 0.80 ± 0.03 0.88 ± 0.03 0.246 64 ± 4 64 ± 3 0.559 
C22:6n-3 3.65 ± 0.14 3.69 ± 0.14 0.886 292 ± 15 276 ± 14 0.602 
       
Saturated 39.41 ± 0.32 40.40 ± 0.17 0.010 3182 ± 139 3059 ± 218 0.670 
Monounsaturated 14.59 ± 0.30 14.49 ± 0.43 0.870 1165 ± 43 1093 ± 82 0.440 
N-3 PUFA 4.82 ± 0.15 4.92 ± 0.18 0.736 386 ± 19 369 ± 18 0.651 
N-6 PUFA 41.19 ± 0.44 40.18 ± 0.49 0.264 3336 ± 162 3043 ± 222 0.382 
PUFA 46.00 ± 0.39 45.11 ± 0.48 0.267 3722 ± 175 3410 ± 236 0.387 
Total 100 100  8068 ± 345 7560 ± 528 0.481 
Abbreviations: N-3 PUFA, omega-3 polyunsaturated faty acids; N-6, omega-6 polyunsaturated faty acids; 
PUFA, polyunsaturated faty acids; Statistical diferences between group means were determined using either 
independent t-tests or Mann Whitney tests, as appropriate. Statistical significance is denoted by P value in 
bold. Data is presented as mean ± standard eror of the mean. 
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Appendix 6 Mean coherence (± SEM) in newborns from control and diabetic mothers at two time points: 24-48 
hours after birth (T0) and 48 weeks post-amenorrhea (T2). 
 
  
Controls 
   
Diabetics 
   Diabetics vs 
Controls 
Electrode 
Pair 
Frequency 
Range (Hz) 
T0 
(n = 22) 
T2 
(n = 17) 
P value 
T2 vs. T0 
 T0 
(n = 4) 
T2 
(n = 3) 
P value 
T2 vs. T0 
 P value 
T0 vs. T0 
P value 
T2 vs. T2 
C3-O1 / 
C4-O2 
0 – 3.4 0.468 ± 0.008 0.466 ± 0.010 0.812  0.450 ± 0.009 0.449 ± 0.019 >0.999  0.471 >0.999 
3.5 – 7.4 0.396 ± 0.004 0.402 ± 0.011 0.566  0.393 ± 0.008 0.393 ± 0.014 >0.999  0.918 >0.999 
7.4 – 12.9 0.394 ± 0.004 0.398 ± 0.008 0.644  0.394 ± 0.006 0.390 ± 0.004 0.857  0.918 0.921 
13.0 – 20.0 0.401 ± 0.007 0.378 ± 0.005 0.009  0.406 ± 0.010 0.385 ± 0.004 0.114  0.707 0.146 
            
Fp1-C3 / 
Fp2-C4 
0 – 3.4 0.548 ± 0.013 0.550 ± 0.014 0.989  0.526 ± 0.022 0.574 ± 0.035 0.229  0.471 0.546 
3.5 – 7.4 0.429 ± 0.007 0.451 ± 0.014 0.221  0.450 ± 0.021 0.455 ± 0.024 >0.999  0.352 >0.999 
7.4 – 12.9 0.398 ± 0.004 0.444 ± 0.009 0.0003  0.400 ± 0.010 0.458 ± 0.018 0.057  0.607 0.765 
13.0 – 20.0 0.382 ± 0.003 0.403 ± 0.005 0.002  0.394 ± 0.003 0.408 ± 0.004 0.057  0.069 0.616 
            
T3-C3 / 
C4-T4 
0 – 3.4 0.438 ± 0.005 0.445 ± 0.006 0.528  0.426 ± 0.009 0.449 ± 0.020 0.400  0.252 0.616 
3.5 – 7.4 0.381 ± 0.002 0.378 ± 0.005 0.190  0.369 ± 0.009 0.370 ± 0.006 >0.999  0.316 0.616 
7.4 – 12.9 0.371 ± 0.003 0.381 ± 0.005 0.172  0.376 ± 0.001 0.385 ± 0.011 0.857  0.256 0.546 
13.0 – 20.0 0.371 ± 0.003 0.368 ± 0.005 0.479  0.376 ± 0.004 0.370 ± 0.006 >0.999  0.352 0.479 
            
T3-Fp1 / 
Fp2-T4 
0 – 3.4 0.513 ± 0.011 0.510 ± 0.013 0.967  0.523 ± 0.022 0.521 ± 0.020 0.857  0.707 0.479 
3.5 – 7.4 0.416 ± 0.005 0.458 ± 0.014 0.010  0.449 ± 0.016 0.451 ± 0.028 >0.999  0.040 0.921 
7.4 – 12.9 0.398 ± 0.004 0.438 ± 0.008 <0.0001  0.410 ± 0.007 0.451 ± 0.010 0.057  0.197 0.616 
13.0 – 20.0 0.378 ± 0.004 0.390 ± 0.006 0.091  0.398 ± 0.010 0.389 ± 0.005 0.629  0.031 0.690 
            
T3-O1 / 
T4-O2 
0 – 3.4 0.425 ± 0.005 0.448 ± 0.007 0.014  0.436 ± 0.011 0.435 ± 0.013 0.857  0.352 0.690 
3.5 – 7.4 0.386 ± 0.003 0.389 ± 0.006 0.790  0.384 ± 0.011 0.384 ± 0.012 >0.999  0.607 >0.999 
7.4 – 12.9 0.388 ± 0.004 0.386 ± 0.006 0.528  0.388 ± 0.006 0.389 ± 0.006 0.857  >0.999 0.479 
13.0 – 20.0 0.394 ± 0.006 0.375 ± 0.007 0.004  0.399 ± 0.005 0.381 ± 0.004 0.057  0.389 0.118 
            
T3-Cz / 
T4-Cz 
0 – 3.4 0.556 ± 0.013 0.565 ± 0.015 0.732  0.550 ± 0.010 0.580 ± 0.018 0.229  0.864 0.765 
3.5 – 7.4 0.506 ± 0.011 0.508 ± 0.015 0.900  0.508 ± 0.031 0.516 ± 0.037 >0.9999  0.973 0.842 
7.4 – 12.9 0.485 ± 0.009 0.508 ± 0.013 0.232  0.482 ± 0.024 0.547 ± 0.043 0.400  0.973 0.479 
13.0 – 20.0 0.441 ± 0.009 0.417 ± 0.012 0.036  0.452 ± 0.015 0.468 ± 0.066 0.857  0.550 0.479 
            
C3-Cz / 
Cz-C4 
0 – 3.4 0.470 ± 0.012 0.509 ± 0.015 0.045  0.481 ± 0.027 0.515 ± 0.032 0.629  0.707 0.842 
3.5 – 7.4 0.433 ± 0.009 0.411 ± 0.008 0.110  0.444 ± 0.020 0.447 ± 0.062 0.629  0.656 >0.999 
7.4 – 12.9 0.428 ± 0.010 0.442 ± 0.009 0.104  0.440 ± 0.022 0.517 ± 0.060 0.400  0.560 0.146 
13.0 – 20.0 0.414 ± 0.009 0.408 ± 0.009 0.748  0.442 ± 0.018 0.483 ± 0.086 0.629  0.082 0.479 
Statistical diferences between group means were determined using Mann Whitney tests. Statistical significance is denoted by P value in 
bold. Data is presented as mean ± standard eror of the mean. 
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Appendix 7 Mean power spectral density (± SEM) in newborns from control and diabetic mothers at two 
time points: 24-48 hours after birth (T0) and 48 weeks post-amenorrhea (T2). 
  Controls    Diabetics    Diabetics vs 
Controls 
Area Frequency 
Range (Hz) 
T0 
(n = 22) 
T2 
(n = 17) 
P value 
T2 vs. T0 
 T0 
(n = 4) 
T2 
(n = 3) 
P value 
T2 vs. T0 
 P value 
T0 vs. T0 
P value 
T2 vs. T2 
Fp1 – C3 
Left 
0 – 3.4 28.8 ± 0.6 29.3 ± 0.6 0.664  28.6 ± 0.3 29.1 ± 0.3 0.229  0.973 0.842 
3.5 – 7.4 21.2 ± 0.4 21.6 ± 0.6 0.705  21.3 ± 0.4 20.9 ± 0.4 0.629  0.973 0.765 
7.4 – 12.9 14.8 ± 0.4 15.0 ± 0.7 0.900  15.5 ± 0.3 15.6 ± 0.5 0.857  0.607 0.616 
13.0 – 20.0 11.6 ± 0.5 11.9 ± 1.0 >0.999  12.4 ± 0.7 14.4 ± 0.3 0.057  0.758 0.479 
0 – 20.0 17.4 ± 0.4 17.8 ± 0.7 0.748  17.9 ± 0.2 18.6 ± 0.1 0.057  0.707 0.690 
            
C3 – O1 
Left 
0 – 3.4 28.1 ± 0.5 32.5 ± 0.6 <0.001  27.3 ± 1.0 32.9 ± 1.5 0.057  0.656 0.616 
3.5 – 7.4 21.0 ± 0.4 23.7 ± 0.6 <0.001  20.0 ± 1.1 23.8 ± 0.5 0.057  0.560 0.690 
7.4 – 12.9 15.2 ± 0.4 14.8 ± 0.5 0.172  15.0 ± 1.0 15.7 ± 1.4 >0.999  0.758 0.690 
13.0 – 20.0 11.7 ± 0.4 10.4 ± 0.6 0.021  11.3 ± 0.6 11.9 ± 3.0 0.629  0.607 0.921 
0 – 20.0 17.4 ± 0.4 18.2 ± 0.5 0.510  16.9 ± 0.9 19.1 ± 1.8 0.629  0.656 0.921 
            
Fp1 – T3 
Left 
0 – 3.4 29.1 ± 0.6 29.9 ± 0.6 0.408  29.4 ± 0.7 29.4 ±<0.1 >0.999  0.918 0.921 
3.5 – 7.4 21.2 ± 0.4 21.8 ± 0.5 0.457  21.6 ± 0.3 21.2 ± 0.3 0.629  0.607 0.921 
7.4 – 12.9 15.0 ± 0.5 15.7 ± 0.6 0.408  15.9 ± 0.2 15.4 ± 0.7 >0.999  0.172 0.690 
13.0 – 20.0 12.3 ± 0.6 13.8 ± 0.9 0.232  13.2 ± 0.6 15.0 ± 0.4 0.114  0.607 0.358 
0 – 20.0 17.8 ± 0.5 18.8 ± 0.6 0.255  18.5 ± 0.3 18.9 ± 0.4 0.400  0.389 0.546 
            
T3 – O1 
Left 
0 – 3.4 27.3 ± 0.5 32.4 ± 0.6 <0.001  27.5 ± 1.1 32.3 ± 1.3 0.057  0.918 >0.999 
3.5 – 7.4 20.0 ± 0.5 22.9 ± 0.5 0.001  19.4 ± 1.0 23.2 ± 0.4 0.057  0.656 0.416 
7.4 – 12.9 14.6 ± 0.5 15.1 ± 0.5 0.475  14.5 ± 1.0 15.8 ± 1.2 0.629  0.973 0.616 
13.0 – 20.0 11.9 ± 0.6 12.6 ± 0.6 0.547  11.8 ± 0.7 13.9 ± 2.7 0.629  >0.999 0.616 
0 – 20.0 17.0 ± 0.5 18.9 ± 0.5 0.009  16.9 ± 0.9 19.5 ± 1.6 0.229  0.973 0.546 
            
Fp2 – C4 
Right 
0 – 3.4 28.8 ± 0.5 29.2 ± 0.5 0.424  29.3 ± 0.5 29.5 ± 0.9 >0.999  0.560 0.842 
3.5 – 7.4 21.2 ± 0.3 21.9 ± 0.6 0.475  21.2 ± 0.5 21.6 ± 1.0 >0.999  0.973 0.842 
7.4 – 12.9 15.1 ± 0.3 15.5 ± 0.7 0.566  15.3 ± 0.5 16.3 ± 0.5 0.229  0.656 0.765 
13.0 – 20.0 12.0 ± 0.5 12.6 ± 1.0 0.604  12.2 ± 0.6 15.3 ± 1.0 0.114  0.973 0.258 
0 – 20.0 17.6 ± 0.4 18.2 ± 0.6 0.475  17.9 ± 0.1 19.3 ± 0.8 0.400  0.811 0.479 
            
C4 – O2 
Right 
0 – 3.4 28.5 ± 0.5 32.5 ± 0.5 <0.001  29.6 ± 1.0 34.1 ± 0.4 0.057  0.352 0.216 
3.5 – 7.4 21.2 ± 0.4 24.0 ± 0.5 <0.001  21.0 ± 1.0 24.0 ± 0.5 0.057  0.973 0.765 
7.4 – 12.9 15.5 ± 0.4 15.2 ± 0.4 0.644  15.7 ± 0.9 15.2 ± 0.4 0.629  0.758 0.765 
13.0 – 20.0 11.8 ± 0.4 10.7 ± 0.6 0.039  12.2 ± 0.4 9.7 ± 0.2 0.057  0.811 0.842 
0 – 20.0 17.7 ± 0.4 18.4 ± 0.4 0.408  18.0 ± 0.8 18.4 ± 0.2 >0.999  0.707 0.616 
            
Fp2 – T4 
Right 
0 – 3.4 29.5 ± 0.6 30.0 ± 0.6 0.362  29.9 ± 0.8 29.8 ± 0.7 >0.999  0.471 0.765 
3.5 – 7.4 21.5 ± 0.4 22.0 ± 0.4 0.392  21.4 ± 0.4 21.6 ± 0.1 0.629  0.973 0.765 
7.4 – 12.9 15.5 ± 0.4 15.8 ± 0.6 0.812  15.6 ± 0.4 16.5 ± 0.5 0.229  >0.999 0.479 
13.0 – 20.0 12.9 ± 0.6 13.9 ± 0.9 0.492  13.0 ± 0.7 16.5 ± 0.4 0.057  >0.999 0.179 
0 – 20.0 18.3 ± 0.5 18.9 ± 0.6 0.528  18.4 ± 0.4 19.9 ± 0.4 0.114  0.864 0.305 
            
T4 – O2 
Right 
0 – 3.4 28.4 ± 0.5 32.1 ± 0.6 <0.001  29.0 ± 0.8 34.0 ± 1.1 0.057  0.515 0.179 
3.5 – 7.4 20.9 ± 0.4 22.7 ± 0.4 0.001  20.0 ± 0.9 23.8 ± 0.5 0.057  0.471 0.146 
7.4 – 12.9 15.3 ± 0.3 14.9 ± 0.4 0.333  14.8 ± 0.8 15.7 ± 0.8 0.629  0.707 0.546 
13.0 – 20.0 12.4 ± 0.4 12.3 ± 0.7 0.748  11.8 ± 0.7 12.6 ± 1.9 >0.999  0.515 >0.999 
0 – 20.0 17.7 ± 0.4 18.6 ± 0.5 0.172  17.3 ± 0.8 19.5 ± 1.0 0.229  0.707 0.305 
            
T3 – C3 
Left 
0 – 3.4 27.3 ± 0.6 28.4 ± 0.7 0.566  25.3 ± 1.2 27.6 ± 1.0 0.400  0.172 0.690 
3.5 – 7.4 20.7 ± 0.5 20.5 ± 0.6 0.392  19.4 ± 1.3 19.5 ± 0.8 0.857  0.471 0.546 
7.4 – 12.9 14.8 ± 0.6 13.1 ± 0.4 0.025  14.6 ± 1.1 12.7 ± 0.6 0.400  0.918 0.842 
13.0 – 20.0 11.0 ± 0.6 10.6 ± 0.6 0.624  11.4 ± 0.5 10.3 ± 1.0 0.400  0.707 >0.999 
0 – 20.0 16.9 ± 0.5 16.4 ± 0.4 0.566  16.5 ± 0.9 15.8 ± 0.7 0.629  0.656 0.842 
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C3 – Cz 
Left 
0 – 3.4 25.9 ± 0.6 26.8 ± 0.7 0.441  26.4 ± 0.8 27.9 ± 0.7 0.229  0.811 0.546 
3.5 – 7.4 20.4 ± 0.5 20.2 ± 0.7 0.664  20.2 ± 1.2 20.4 ± 0.7 0.857  0.864 0.690 
7.4 – 12.9 14.1 ± 0.5 12.5 ± 0.6 0.082  14.9 ± 0.8 13.7 ± 1.2 0.629  0.429 0.479 
13.0 – 20.0 9.1 ± 0.6 6.4 ± 0.6 0.003  10.4 ± 0.2 7.5 ± 2.3 0.629  0.283 0.921 
0 – 20.0 15.7 ± 0.5 14.5 ± 0.6 0.172  16.5 ± 0.6 15.4 ± 1.3 0.629  0.607 0.765 
            
Cz – C4 
Right 
0 – 3.4 26.0 ± 0.6 27.1 ± 0.5 0.492  27.3 ± 0.7 27.8 ± 1.3 0.857  0.560 0.615 
3.5 – 7.4 20.5 ± 0.5 20.7 ± 0.6 0.989  20.5 ± 1.4 20.5 ± 1.3 >0.999  >0.999 >0.999 
7.4 – 12.9 14.4 ± 0.5 13.0 ± 0.6 0.092  14.9 ± 1.3 13.7 ± 0.8 0.400  0.560 0.690 
13.0 – 20.0 9.3 ± 0.5 7.2 ± 0.6 0.023  10.5 ± 0.7 7.6 ± 1.8 0.400  0.252 0.921 
0 – 20.0 15.9 ± 0.5 15.1 ± 0.6 0.221  16.7 ± 1.0 15.5 ± 1.1 0.629  0.471 0.690 
            
C4 – T4 
Right 
0 – 3.4 28.0 ± 0.5 28.8 ± 0.5 0.221  27.0 ± 1.2 29.3 ± 0.3 0.114  0.471 0.616 
3.5 – 7.4 21.3 ± 0.4 21.1 ± 0.5 0.457  19.1 ± 1.3 20.2 ± 1.1 0.857  0.130 0.690 
7.4 – 12.9 15.5 ± 0.4 14.0 ± 0.4 0.009  14.0 ± 1.4 13.6 ± 1.0 0.857  0.471 0.921 
13.0 – 20.0 11.9 ± 0.4 11.1 ± 0.7 0.117  10.8 ± 1.0 10.7 ± 2.2 >0.999  0.352 0.842 
0 – 20.0 17.7 ± 0.4 17.0 ± 0.4 0.292  16.2 ± 1.2 16.7 ± 0.9 >0.999  0.471 >0.999 
            
T3 – Cz 
Left 
0 – 3.4 29.6 ± 0.5 30.4 ± 0.6 0.408  29.4 ± 0.9 30.9 ± 0.5 0.229  0.918 0.690 
3.5 – 7.4 22.8 ± 0.4 22.6 ± 0.6 0.492  22.2 ± 1.1 22.7 ± 0.8 0.857  0.811 0.921 
7.4 – 12.9 16.4 ± 0.5 15.5 ± 0.4 0.292  16.7 ± 0.8 15.8 ± 0.7 0.629  0.471 0.842 
13.0 – 20.0 12.1 ± 0.5 11.8 ± 0.6 0.769  13.0 ± 0.3 12.2 ± 1.1 0.629  0.223 0.842 
0 – 20.0 18.5 ± 0.4 18.3 ± 0.5 0.790  18.8 ± 0.7 18.6 ± 0.6 >0.999  0.429 0.765 
            
T4 – Cz 
Right 
0 – 3.4 30.0 ± 0.5 30.6 ± 0.5 0.377  29.7 ± 0.8 31.0 ± 0.7 0.629  0.918 0.616 
3.5 – 7.4 23.1 ± 0.4 22.8 ± 0.5 0.305  22.0 ± 0.9 22.8 ± 0.8 0.629  0.352 0.842 
7.4 – 12.9 16.7 ± 0.4 15.5 ± 0.4 0.052  16.3 ± 0.9 16.3 ± 0.5 0.629  0.973 0.479 
13.0 – 20.0 12.7 ± 0.4 11.8 ± 0.6 0.087  12.5 ± 0.6 12.7 ± 1.9 0.857  0.973 0.616 
0 – 20.0 19.0 ± 0.4 18.3 ± 0.4 0.305  18.5 ± 0.7 19.0 ± 0.6 0.629  0.811 0.616 
Statistical diferences between group means were determined using Mann Whitney tests. Statistical significance is denoted by P 
value in bold. Data is presented as mean ± standard eror of the mean. 
 
